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ABSTRACT
Breast cancer is the leading form of cancer among women in North
America. The development of resistance to endocrine lherapy as well as
chemotherapy is presently the major obstacle to successful treatment of
advanced breast cancer. Therefore, more potent and selective
chemotherapeutic agents should be designed. An attractive solution to this
problem is to combine both endocrine therapy and chemotherapy in a single
agent. 11 may resull in a more powerful approach to advanced breast cancer
treatment.
In order to achieve this goal. a series of new lriphenylethylene platinum (II)
complexes 39a-d, 40a-c and 41 have been designed and synthesized. The
commercially available benzyl, 4-hydroxyphenyl ketone was efficiently
transformed in eight sleps into the platinum (II) complexes 39a-d with an overall
yield of around 30%. In a similar sequence of reactions, the complexes 40a-c
and 41 were also synthesized. the overall yield exceeded 40%. All new
compounds were fully characterized by thf:lir infrared and 1H, 13C nuclear
magnetic resonance and mass spectra, The final compounds 39a-d, 40 ..-c and
41 also passed element analysis.
The biological activity of the complexes 39a-d, 40a-c and 41 were
evaluated .iD...::illrQ on both ER+ and ER- breast cancer cell lines: MCF-7 and
MDA·MD·231, The complexes 40b-c showed promisin9 antitumor activity.
Their ICso is up to 28 fold lower than tamoxifen on MDA-MD·231, and 3 fold
lower on MCF-7. However, there was no evidence of selective antitumor activity
on ER+ breast cancer cell io.:ii1r2,
ii
ACKNOWLEDGEMENTS
t would like 10 extend my sincere appreciation to my supervisor, Dr.
Gervais Berube, for his many hours of helpful instruction and discussion during
the course of rny research project.
Special thanks are given 10 Ms. Roberts, Dr. Kantha Arunachalam, Achilles
Lau, Stephen Sherman, eida Zhao, Oongyuan Yao, Sue Ellen Maher and John
Bautista for their support, encouragement, and friendship,
I am grateful 10 Ms. Natalie Brunet for 300 NMR spectra, Ms. M. Baggs,
Dr. Liang Tang and Dr. Feimeng Zhou for mass spectra. Special
acknowledgement is given 10 Dr. Rene C.-Gaudreault and Mr. Jacques Lacroix
for biologicallestlng. r thank my supervisory committee, Or. Ford and Dr.
Loomis for their support during my study. I would like to thank Departement de
Chimie-Biologie, Universite du Quebec a Trois-Rivieres for providing me
laboratory space to accornplish my research work,
Sincere thanks are due to Mrs. Daphne Efford for her help and friendship,
I am deeply grateful to my husband, my parents tor their love, support, and
encou~agement.
The financial support from School of Pharmacy, Memorial University of
Newfoundland in the form of a Memorial Graduate Fellowship and Medical
Research Council of Canada is gratefully acknowledged.
iii
lille
Abslract
Acknowledgements
Table of ConIenIs
Ust of Figures and Table
UstofSchemes
Ust of Spectra
Glossary of Abbreviations
Dedication
TABLE OF CONTENTS
vii
Chapter 1 INTRODUCTION
Chapter2 RESULT AND DiSCUSSION 21
2.1 Synthesis of Bishydroxy and Bismelhoxy
Triphenylelhylene Plalinum(lI) Complexes
39a·d and 41 21
2.2 Synthesis 01 Triphenylelhylene
Plalinum(lI) Complexes 40a-c 26
2.3 In Vitro Antitumor Activity 33
2.4 Conclusion 38
ChapterJ EXPERIMENTAL 39
3.1 Synthesis 39
3.2 In Vitro Antitumor Activity 87
REFERENCES 69
APPENDIX 78
Lv
LIST OF FIGURES AND TABLE
Figure
Immullotargeting with MAb for The Treatment of Cancer
Estrogen Effects on Breast Cancer cell
The Mechanism of Anlieslrogen Action for the Treatment
of ER+ Breast Cancer cell
Page
The lIluslration of the Interaction of the Non-Steroidal PI (II)
Complex with the ER and DNA 19
The Structure of the New Anlieslrogens IC1164, 384 and
IC1182,780 19
1H NMR Spectra of Compounds 55e and 56e 31
13C NMR Spectra of Compounds 55e and 56e 32
The Reaclion Equation of MTT Aeduction 33
MCF·7 Cell Survival Curves 36
10 MDA-MB-231 Cell Survival Curves 37
Table Page
Inhibitory Concentration of Drug on both EA+ and ER- Breast
Cancer Cell Lines 34
Scheme
UST OF SCHEMES
vi
Page
21
22
25
26
28
30
LIST OFSPECTRA
Spectrum page
IR of compound 46a 77
IR of compound 48a 78
IR 01 compound 49a 79
IR of compound 50a 80
tA of compound 39a 81
IA of compound 41 82
lA of compound 53c 83
IA of compound 55e 84
IA of compound 56e 85
IR of compound 57c 88
IR of compound 58c 8i'
IR of compound 40c 88
1H NMR of compound 46a 89
1H NMR of compound 48a 90
1H NMR c.f compound 49a 91
1H NMR of compound SOa 92
1H NMR of compound 39a 93
lH NMR of compound 41 94
1H Nt.4R of compound 53c 95
1H NMA of compound 55e 98
1H NMA of compounC: 56e 97
vii
1H NMR of compound S7c 98
1H NMA of compound sac 99
1H NMR of compound 40c 100
13 C NMR of compound 46a 101
13 C NMA of compound 48a 102
13 C NMA of compound 49a '03
13 C NMR of compound SOa '04
13 C NMR of compound 39a '05
13 C NMR of compound 41 100
13 C NMR of compound S3c 107
13 C NMR of compound SSe 108
13 C NMA of compound 56c 109
13 C NMR of compound 57c 110
13 C NMR ot compound sac 111
13 C NMR of compound 40c 112
viii
dd
OHP
OMF
OMSO
E2
EGFR
ER
ER+
ER-
ERBA
ERE
Et
hr
rGF
IR
m
MAb
Me
mp
MS
MTT
GLOSSARY OF ABBREVIATIONS
doublet
double doublet
dihydropyran
N, N·dimelhylformamide
dimethyl sulfoxide
estradiol
epidermal growth factor receptors
estrogen receptor
estrogen receptor positive
estrogen receptor negative
estrogen receptor binding affinity
estrogen response elements
ethyl
hour
insulin like growth factors
infrared spectroscopy
multiplet
monoclonal antibody
methyl
melting point
mass spectroscopy
3- (4,5·dimethylth iazol-2-yl) -2,fi·diphenyltetrazolium bromide
NMR nuclear magnetic resonance spectroscopy
PBS phosphate·buff~red sartne
Ph phenyl
PPTS pyridinium, para·!oluenesulphonate
pTSA para·toltienesulphonic acid
quartet
RPMI Roswell ?Rrk Memor;allnstitute
singlet
TGF tumor growth lactors
THF tetrahydropyranyl
THP letrahydrofuran
TLC thin layer chromatography
TMS telramethylsilane
TPA triphenylacrylonilrile
TO MY HUSBAND AND MY PARENTS
YO/} MAKE ITALL WORTH IT
xi
Chapter 1
INTRODUCTION
Breast cancer is the most common form of cancer among women in North
America. In 1994, if is estimated that 17,000 women will be diagnosed with
breast cancer in Canada, representing approximately 30% of new cancer cases
for all sites. Of the 27,600 cancer deaths, approximately 5,600 (20%) will be
caused by breast cancer.' Therefore, finding an effective method to treat breast
cancer is an important and urgent mailer.
Currently, surgery with adjuvant radiotherapy is quite effective to freat
breast cancer when the tumour has not metastasized by the lime 01 treatment..
However, even in the best circumstance, ten year survival rates of 50% have
been unusual and some ·clinical cures· may recur with fatal oufcome as late as
twenty years with such localtreatmenl.2 Therefore, a systemic approach such
as chemotherapy plays an important role for a more effective cancer
management.
At present, different types 01 drugs are used in chemotherapy, such as
alkylating agents, DNA-intercalating agents, antibiotics, antimitotic agents,
antimetaboliles and so on. An ideal anticancer drug would eradicate cancer
cells without harming normal tissues. Unfortunately, no currently available
agents meet this criterion and clinical use of these drugs involves a weighing of
benefits against toxicity in a search for a favorable therapeutic index.3
Another major problem in cancer chemotherapy is drug resistance, which
means that lumors no longer respond to presently available chemotherapeutic
agents. It is estimated that over 90% of af! cancer death are, in some measure,
influenced by the problem of drug resistance.4 Some mechanisms of drug
resistance have already been identified in human tumor cell lines. They include:
decreased transport,S altered drug ac!ivation,6 altered DNA repair,7 gene
ampHfica:ion,6 defective drug melabolism,9 altered target proteins and altered
intracellular nucleotide pools. to Faced with the complexity of the drug
resistance mechanisms already identified, one might conclude that
circumventing drug resistance is not a likely possibility.
An allracljve solution which is being considered to solve these two
problems is the use of drug targeting. The aim of drug targeting is to deliver
drugs only to those sites needing treatment. When this objective is met, not only
toxic side effects will be minimized, but the efficacy of the treatment will be
impro~ed. Therefore, the tumor might be eradicated rapidly before any sign of
msistance occurs.
Fig.1 lmmunotargetlng with MAb for the treatment of cancer.
The concept of drug targeting was- first suggested by Paul Ehrich in the
early 1900's.11 He proposed that chemotherapeutic agents might be covalently
joined to ligand substrates which had affinity for and selectivity to a target tissue
such as malignant tumors. Since then, some biological and chemical molecules
have been tried as ligand substrates for anticancer drug targeting, such as
monoclonal antibodies (MAb). By covalently linking antitumor agents to MAb
reactive wilh tumor-associated antigens, these drugs can be targeted 10 the
tumors (Fig.1).12 Numerous scientists are still working on this area.
The presence of substantial amounts of estrogen receptors (ER) in many
human breast tumors is well known and is being used to select Ihe most
appropriate therapy such as endocrine therapy and/or chemotherapy for breast
cancer patients.13 These receptors provi.de a potenlial.largeling mechanism by
which agents with estrogen receptor binding affinity (ERBA) could be
concentrated selectively In the tumor tissue. For example, several groups have
developed "(-emitting estrogens as diagnostic imaging agents for human breast
cancer. 14 It might also prove possible 10 prepare conjugates of molecules with
ERBA and cytotoxic agents, which would bind to ER and would thus
concentrate their cytotoxic activity wilhin ER-conlaining cells, sparing cells in
nontarget tissues. It is this prospect of achieving a selective ER mediated killing
of ER positive (EA+) breast cancer cells thai has concerned scientists in the
area of breast cancer. This thesis is also devoted to preparing this type of
antitumor a~ent.
The development of antitumor agents wilh EF'IBA for breast cancer has
some encouraging experimental precedent. As early as the 1950s, several
scientists have been trying to link nitrogen mustard (1), an alkylating agent, 10 a
variety of steroid nuclei such as cholesterol (4), estrone (5), testosterone (6),
Nitrogen Mustard
°H II Cl
"r/'-...I/'../
R NO
NitrosQureas
H3N'p(CI
HJN"" .... Cl
Cisplatin
.#
R=H Cholesterol
°R=AN~Cl
~CI
R=H Testosterone
R=H Estrone
# ORH "uOH
° '"
R=H Hydroconisone
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and hydrocortisone (7) to treat hormone dependent breast cancer.
Unfortunately, the compounds obtained, Le., 8,15 9,16 10 17 an d 1118
displayed only moderate antitumor activities. 11 is believed that these steroid
nuclei are not the most appropriate ligand for the ER.
OH
"~
12 Estradiol (Ez)
Since the discovery of estradiol (12), the endogenous ligand for the ER,
numerous allempts were made to conjugate it to alkylaling agents. In the early
attempts, aJkylating agents such as nHrogen mustard (1), nitrosoureas (2), and
cisplatin (3) were linked to the 3· and 17-position of the estradiol skeleton.
However, the compounds obtained 13,19 14,19 15,20 16,21 1722 and 1823
showed only low biological activities against ER+ breast cancer.
Structure activity relationship studies of various estrogenic compounds
have shown that in order to obtain the highest ERBA, the estrogenic steroid
hormone with an estra-1,3,5(10)-triene-skeleton must have the 3- and 17p-
hydrox.y groups available, presumably to form hydrogen bonds with the receptor
protein at the binding sites.24 Therefore, it has been suggested that the
relatively weak antitumor activities of those agents against breast cancsr were
partly due 10 Iheir inability to bind to the ER and thereby to accumul~te in ER+
trssues.25 Simply, the cytotoxic moiety was inappropriately linked to the binding
13 14
IS 16
17 18
,. 20 Lomuslinc
siles of estradiol, namely carbon 3 and/or 17.
In order 10 relain the 3- and 1713-hydroxy groups on the estradiol (E2)
nucleus, a nitrosourea (2) moiety was introduced at Ihe 17a.·posilion.20 As
expected, the resulting compound 19 had higher ERBA value th;m the 1713·
derivative 15 (19=1.8%, 15=0.41%, E2=100%).26 The order of ERBA also
correlates with the order 01 cytotoxicity against ER+ breast cancer. Moreover,
compound 19 was more active than the mixture 0' estradiol and lomustine (20),
the latter being a clinically useful antitumor nilrosourea.26 Unfortunately, the
estrogenic activity induced by this product made it less attractive since it could
cause cardiovascular and other toxic side effecls.27
With the various studies of hormonal influence on breast cancer cell
growth. one question has been pul forward: "Is an estrogenic molecule such as
estradiol a good carrier of antitumor agents 1"
There is considerable evidence to suggest that estrogen has direct and
indirect effecls on proliferation of ER+ breast cancer cells (Fig.2).28.29 Estrogen
can bind 10 the estrogen receptor 10 unmask the DNA binding domain. This
domain can bind 10 the estrogen response eiements (EREs) on the DNA 10
initiate the transcription of estrogen-sensitive genes and prolein synthesis.
Estrogen can also increase the production 01 tumor growth factors alpha (TGFa)
that possibly interacts with epidermal growth factor receptors (EGFR) in an
autocrine loop. Similarly, estrogen causes a decrease in !:oome members of the
TGFp family which is a tumor suppressor.
Flg.2 Estrogen effects on breast cancer cell.
Alternatively, antiestrogen has ERBA, but no estrogentlc activity. Therefore,
anliestrogen can act as a competitive inhibitor of estrogen binding to the ER to
prevent estrogen-stimulated changes in cellular biochemistry .29 Until now,
three mechanisms of antfestrogen action wore proposed: antiestrogen, A.
reduc~s DNA binding by interfering with receptor dimerization (Fig,3, A);30 8.
induces conformational changes of the receptor that allow binding to DNA but
do not promote events needed for geile transcription (Fig.3, 8);31 C. causes a
rapid disappearance of the ER from the target tissue, resulting in an insufficient
amount of ER to bind the native ligand and elicit agonistic responses (Fig.3,
C).32 Consequently, the blockage of estrogen action with antiestrogen remains
a generally accepted method 01 treatment of ER+ breast cancer.
A c
Fig.3 The mechanism of antiestrogen acllon for the treatment of ER+
breast cancer cell.
From these points of view, Katzenellenbogen thought thal33 the
syntheses of new conjugates containing both antlestrogenic and cytotoxic
moiety could be of prime interest. Simply, an antiestrogenic moiety would not
only be used as the carrier of cytotoxic agents, but also could produce potential
antitumor activity by itself. It may result in a powerful drug for the treatment of
ER+ breast cancer.
Therefore, Katzenellenbogen and his co-workers selected tamoxilen (21),
an antiestrogenic agent which Is widely used for the treatment of EA+ breast
cancer, as a carrier Clf toxic moieties to produce new anllcancer drugs.33 ,35
Alkylating agents such as nitrogen mustard, nitrosourea, nitrosocarbamate were
linked on the alkoxy side chain of tamoxifen because the ethyl side chain was
found necessary for antiestrogenic act.ivity.34 Two a.nalogues, the nitrogen
mustard·tamoxifen 22 and the nitrosoc&rbamate-lamoxifen 24 showed dose
related cytotoxicity in both ER+ and EA- breast cancer cell lines: MCF~7 and
MDA·MB·231, which was nol suppressed by estradh')l. However, lamoxifen·
nitrosourea 23 demonstrated malted cytotoxicity in MCF-7 cells that was
blocked by estradiol, whereas its activity in MDA-MS·231 celts was unaffected
by estradiol. It seemed thai the selective toxic activity of 23 agailst EA+ cell line
was mediated via the EA. However, recent evidence suggested that the
cytotoxicity of 23 resulted from the antiestrogenic effect of its hydrolysed
product, bisdesmelhyltamoxifen 25,35
21 TamoJtifen
OR
o...............NH2
2S Bisdesmethyl Tamoxifen
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The reason for these analogues of tamoxifen to be devoid of selectivily for
ER+ breast cancer cells was rationalized by their low ERBA. As mentioned by
Katzenellenbogen,36 for a cell to be killed using a receptor uptake process, an
adequate dose of drug must be delivered by the receptor system. However, the
capacity of the ER uptake system is quite limited. From clinical assays on
human breast tumors, it is known that Ihe range of receptor contenl is 1000-
10000 per cell. The calculation based on the number of ER and the possible
drug concentration per cell demonstrates that the ERBA value of drugs should
be at least 1% of estradiol (E2=100%).37 But the ERBA assay of the compounds
22, 23 and 24 on MCF-7 cefllines showed the EABA values of only 1.2%,
0.35% and 0.19% respectively.33.3S From this point of view, tamoxifen might not
be a good carrier of antitumor agents for ER+ breast cancer since derivatives
based on a relatively low affinity ligand would also have relatively low aWnlty
(The ERBA value of tamoxifen is only 1.8% of E2).36
More recently, German scientists, Knebel and co-workers, thought that a
non-steroidal structure, 5-hydroxy-2-(4'·hydroxyphenyl)-3-methylindole (26)
might be a suitable derivative to link a cytotoxic agent to because of jls structural
similarities with zindoxifene (27, ERBA=9.5% of E2),38 a drug which has been
developed as an anliestrogen.37 Moreover, it also showed high ERBA, Le., 33%
of E2.39 They found that the nitrogen atom waG the best position for the
introduction of bulky substituents into the indole skeleton without much
interference with the Importal'll binding sites of the molecule (C·S·OH and C-4'-
OH).41 The cytotoxic moiety was linked to the Indole skeleton by a spacer
group in order to avoid strong sterle Interaction of the ligand with the ER binding
sites. In their model, a cis·(diaminoalkane) dichloropiatinum (Il) complex was
used as the cytotoxic moiety. The parent compound cisplatin (3) is a potent
11
antineoplastic agent against solid tumors, especially testicular cancer,42 but
hao low activily againsl breast cancer.43 Moreover, cisplatin induces very
serious side elleets such as nephrotoxicity44 and ototoxk:ity45. They believed
that the affinily of the new platinum complexes for the ER mighl increase the
activity of such an agent on mammary tumors and reduce its toxic side effects.
The compounds synthesized (28a-c) showed some specific binding affinity for
the ER.46 The relative ERBA values of the compounds 28a, 28b, 28c were
1,0%, 1.3%,6.5% respeclively. The order of their ERBA values correlated with
the order of theircytotoxicily.47 Jill1t.m, only the growth ofER+ MCF·7 mammary
tumor cells was inhibited, whereas EA- MDA-MB-231 cells did not respond,!n
~, a slrong inhibitory effect was observed in ER+ MXf mammary tumors of
the mouse, The complex 28c, with six carbon alom side chain, reduced the
lumor weight by 89% after six weeks of treatment (The dosage was 3x20 mglKg
body weight/ week,). The effect on EA- tumors was weaker than on ER+
tumors.47 The complexes 29 and 30 also showed inhibitory effect similar to the
complex 28c (the ERBA value of 29 and 30 =5.2% and 4.4%, E2=100%),48,49
Moreover, there was no sign of neph rotoxicity observed in these experiments
(usually cisplatin induces a serious nephrotoxic side effect),
These findings were rationalized by the specific binding affinity of those
complexes. However, the antitumor aclivities of lhose complexes were still
slightly less active than cisplalin itself-which was used in subtoxic dosage
(3x1.4 mg/Kg body welghVweekj. Therefore, It has been suggested that further
Investigation of steroidal or non-sleroidal derivatlves to link anticancer agents
should be focused on the development of drugs with further improved
antineoplastic acllvity based on enhanced EABA, This could be achieved by
coupling antineoplastic drugs 10 hormonal derivp.tives with relatively slrong
12
ERBA50
26
29
13
27 Zilldoxifcnc
2S
Q=4 (ll},S(b),6(c)
Htr5-0--I ~ ;) OH~ N
~~
H~, .NH1
....... Pt ....
CI CI
30
In 1987, A. GustS1 and J. KarlS2 successfully synthesized two new
powerful horm::mal platinum complexes, namely meso-[1 ,2-bis{2,S-dichloro-4-
hydroxyphenyl) ethylenediaminej dichloroplalinum (II) complex (32) and meso-
[1 ,2-bis(2,S-dichloro-4-hydroxyphenyl) ethylenediamine] disulfatoplatinum (II)
complex (33) for the lreatment of EA+ breast cancer. They selected hexestrol
(:::1), a non-steroidal synthetic estrogen as a ligand substrate to link the
cytotoxic moiely, platinum (It) complex. In comparative tesis on ER+ and ER-
mammary tumors in cell culture (MCF-7 and MDA-MB-231 cell lines), the
complexes 32 and 33 were not obviously selective, inhibiting both ER+ and ER-
mammary carcinoma. However, In vivo, a strong inhibitory effect of 32 was
observed in EA+ MXT mammary tumors of the mouse. After four weeks of
treatment at a dosE' of 3x6.5 mg/Kg body weighVweek, the tumor weight was
reduced by 88%, which was significantly more active than cisplatin at the
highest tolerable dosage (3x1.5 mg/kg body weightlweek). A further increase of
efficacy was achieved with th& water soluble sulfatop latinurn complex 33.
Moreover, they also displayed inhibitory activity for prostatic -,ncer.53
Preliminary biological studies of the complexes 32 and 33 showed that
their high antitumor activity lor EA+ breast cancer resulted from their ER
mediated enrichment in the nuclei of ER+ tumor cells. A higher level of Pt in the
tumor tissue than in skeletal muscle and blood was found.52,54 Moreover, both
derivatives displayed estrogen-like propertie$:55 a) it competed with estradiol
lor EA binding siles in a competitive manner at 0.1 lJM concentration; b) it
reduced the number of estradiol binding sites after a 16 hours incubation, and
c) It increased the level of progesterone receptor. However, their relatively low
EABA (the EABA value of 32 and 33 = 0.3%, 0.1% respectively, E2=100%)52 is
Inconsistent with the enrichment theory. It suggests that the 1% EABA threshold
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minimum level might not be necessary for selectivity. II is acceptable that the
complexes 32 and 33 might bind to an ostrogen-specific nuclear receptor,
which also could cause an enrichment in the nucleus giving rise to an
increased reaction with DNA.52 Recent studies suggested thai the selective
growth inhibitory effects 0132 and 33 atso involved immunological factors.55,56
Hexestrol 31
32
15
33
Interestingly, the isomers of 32, namely ..d,I-[1,2-bis(2,6-dichloro~4­
hydroxyphenyl) ethylenediamine) dichloroplatinum (II) complex displayed
neither estrogenic activities nor cytotoxic effects for EA+ breast cancer.52 The
exact mechanism!' of their actions are still unclear. Numerous scientists are
continuing to working in this area.
Although the new platinum complexes 32 and 33 display powerful
antitumor activity against ER+ breast cancer, their estrogenic properties
become a major obstacle in their clinical use.57 As mentioned before,
estrogenic acfivily can cause cardiovascular side effects. H. Schonenberger
and co-workers are trying to modify the structure of the 1,2-diphenyl-
ethylenediamine ligand In order to reduce its strong estrogenic potency.57
34 ERDA= 18
H
35 ERBA = 71
H
36 ERBA =270
16
H
37 ERDA =270
H
OH OH
'"OH b
""I '"
'" ""
0-..
'"
H H
d' (h
HN NH:,/
/Pt.........
CI CI
38 39
n= 6{.), 8(b), 10«) n= 6(.), 8(b}, 10«), U(d)
40
n= 6(.), 8(b), 10«)
17
H,C
41
In this thesis, we are describing our efforts towards the design of new
cisplatinum complexes with good EABA. According to the enrichmenllheory,
high EABA is needed to result in a sufficient accumulation of drugs in the ER+
tumor tissue through the EA mediated transport process.36.37
Pons and co-workers investigated the relationships oi structure and EABA
of a vClriety of non-steroidal estrogen derivatives.58 They found that
hydroxylated triphenyJacrylonitriles (TPA) had high EABA, particularly the
compounds 36 and 37 (the EABA value of 36 and 37=270, E2=100). These
studies suggest that TPA analogues 36 and 37 could be good candidates to link
antitumor agents to because according to Von Angerer's findings, derivatives
basl3d on relatively high affinity ligand should also possess relatively high
affinity.36
Therefore, we design a series of new cisplatinum complexes 38a-o and
39a-d which are linked to the non-steroidal sk6Jelon. TPA . We hope that these
new cisplatinum complexes will have higher ERBA, therefore, higher antitumor
activity against ER+ breast cancer than the platinum complex 28 synthesized by
the German scientists.
The cytotoxic moiety, ethylenediamine platinum (II) complex, will be
linked on the middle part of TPA skeleton in order to avoid strong sterle
interference with the important binding sites of the carrier ligand, I.e., the
hydroxy groups. Long side chains with six, eight, ten or eleven carbon atoms
will be added between the two portions: TPA skeleton and clspJatinum (II)
complex. This should allow the two portions to be more flexible to react with the
estrogen receptor and DNA respectively (FigA), The length and position of the
side chain are also based on the structure of the pure steroidal antiestrogens
IC1164,384 and ICI182,780 (Fig.S) recently described in the literature.59 Such
18
estradiol with a long alkyl side chain on the 7-« position possesses sufficient
ER8A (the EABA value of ICI 164,384 and ICI182,780=19'ro, 89~o respeclivefy,
E2=1000/0)60 and pure antlestrogenic activity. A pure anliestrogen is devoid 01
any estrogenic ?ctivity, therefore no estrogenic side effects will be induced. This
structural analogy should confer upon our new compounds both anliestrogenic
and. cytotoxic activity.
FIg.4 The Illustration of the Interaction of the non-steroidal Pt (II) complex
with the EA and DNA.
o
n
R= -(CHVIOC~{CH2hCHJ lei 164,384
CH)
o
II
R= -(CH2~S(CH2)JCF2CFJ leI 182,780
Flg.S The structures of the new antlestrogens IC1164,384
end ICI182,780.
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TPA-clsplatinum (JJ) complexes 40a-c and 41 without hydroxy groups will
also be synthesized. They will be our reference derivatives. Such compounds
should have no ERBA and no hormonal activity. Their biological activity wilt be
solely produced by their platinum portion. Therefore, it may help us to
understand the possible mechanisms of actions of the compounds 3Ba-c and
39a-d containing hydroxy groups. Moreover, il may also help us 10 estimate the
ERBA values of 3Ba-c and 39a-d more precisely since il is known thai platinum
complexes might produce non-receptor irreversible binding to proteins in the
ER preparation.51
In our laboratory, we havo already obtained Ihe complexes 38a-c.62 In this
project, we are going to report the synthesis of the remaining compounds 39a-d,
40a;-c and 41, as well as their in vitro biological activities on MCF-7 (EA+) and
MDA-MD-231 (EA-) human breast cancer cell Jines.
20
Chapler2
RESULTS AND DISCUSSION
2.1 Synthesis of Bishydroxy and Blsmethoxy Triphenylethyrene
P~atlnum (II) Complexes 39a-d and 41.
As shown in Scheme 2, four new platinum (II) complexes 39a-<l were
obtained with a 30% overall yield from commercially available benzyl, 4-
hydroxyphenyl ketone, after eight sleps.
Scheme 1
DHP, PPTS
Br-(CH2)n-OH~
CH1CI2
42 43
N,1
--Acetone
I-(CH"n-o-.(r'J
o
44
0= 6(0), 8(b), 10(e), lI(d)
Initially the appropriate iodotetrahydropyranyl ethers 44a-d were prepared.
As illustrated In Scheme 1, the alcohols 42a·d were protected as a
tetrahydropyranyJ ether to give compounds 43a·d,63 which, upon treatment with
21
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sodium iodide in dry acetone, gave the Jodotelrahydropyranyl ethers 44a-d
(95% average yield for the two steps).
Benzyl-4-hydroxyphenyl ketone cannot directly be used as the starting
material in alkylating reaction (II, Scheme 2) since the existence of hydroxy
group is able to quench the enolation of the ketone.54 So we protected the
hydroxy group as a methyl ether 45 by using dimethylsulfate and sodium
hydroxide (I, Scheme 2).65 The yield for this reaction was around 75% (98%
based on the recovered starting material ketone).
Alkylation of 45 with the iodotetrahydropyranyl ethers 44a-d was achieved
using sodium hydride in letrahydrofuran to give compounds 46a-d with an
average yield 01 75% (98% taking consideration 44a-d recovered (II, Scheme
2). Addition 01 an excess of p-methoxyphenylmagnesium bromide to the
ketones 46a-d (III, Scheme 2)65 and subsequent treatment of the crude tertiary
alcohol intermediates 47a-d with pyridinium-p-toluenesulfonate (PPTS) in
ethanol at reflux afforded the triphenylethylene alcohols 48a-d (IV, Scheme 2)
as the result 01 dehydration of the tertiary alcohols and simultaneous
deprolection of the tetrahydropyranyl ethers (85% average yield for the two
steps).63
Wilh the desired triphenylethylenes 48a-d in hand, the following sequence
of reactions are simple functional group transformations. Initially, alcohols 48a-d
were transformed to the bromides 49a-d with carbon tetrabromide and
triphenylphosphine in dry dimethylelher (85% average yield. V, Scheme 2).67
The amines 50a-d were obtained with an average yield of 90% by refluxing the
bromides 49a-d in the presence of an excess of ethylenediamine in dry
methanol (VI, Scheme 2).68 Finally, demethylation with boron tribromide gave
the intermediate bis-phenols 51a-d (VII, Scheme 2),69 which, upon treatment
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with potassium tetrachloroplalinate (11) in a mixture of dimelhylformamide (DMF)
and water (VIII, Scheme 2), led to the desired platinum (II) complexes 39a-d
(60% average yield for the two steps).70
Scheme 3
SOd 41
The platinum (II) complex 41 was easily obtained by reactfng the amine
SOd with potassium tetrachloroplatinate (II) in a mixture of DMF and water
(Scheme 3. 80% yield)),
All new compounds obtained were characterized by their lA, 1H NMA, 13C
NMR and Mass spectrum, The final products 39a-d, and 41 passed element
analysis (C, H, N).
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2.2 Synthesis of Triphenylethylene Platinum (II) Complexes 40a-c.
The lriphenylelhylene platinum (II) complexes 40a-c were synthesized
from commercially available starting malerial deoxybenzoin 52 (Scheme 4), in a
similar sequence of reactions as used earlier for compounds 39a-d. The tolal
yield exceeded 40%.
Scheme 4
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25°C, 6 hrs; (III) 95% ethanol, PPTS, reflux, 3 hrs; (IV) toluene, pTSA, rcfluit, 2 hes;
(V) CBr4' PhJP. dielhyl ether, 25°C, 24 hrs; (VI) ethylenediamine, methanol, reflux,
48 hrs; (vn) KzPtCI4 , DMF, H20. 25°C, 48 hrs.
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One reaction which we would like 10 emphasize here is Ihe dehydration
and deprotection of the tertiary alcohols 54a·c (III, IV. Scheme 4) because it is
quite interesting.
Scheme 5
54,
Y::
«n"\,EIOH
'"
SSe
56,
pTSA
Toluen reflux
Initially, we followed the same procadure as for the dehydration and
deproteclion of 47a-d (IV, Scheme 2). The tertiary alcohol54c was allowed to
feact in the presence of PPTS in 95% ethanol at reflux for 8 hrs (Scheme 5). We
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expected simuJlaneous dehydration of leniary alcohol and deprotection 01 THP
elher 10 form Ihe alkylalcohol 56c. Unfonunately it was not the case. The IR
spectrum of the product obtained showed a broad absOfption at 3600·3300 em·
1 suggesting the presence of hydroxy group. If the product was 56c, a al1ylic
methylene should appear around a 2.43 in ils 1H NMR. Five quaternary
carbons should also be observed between a 150.00 and 135.00 in Us 13C
NMA. However, there was no signal at a 2.43 in Ihe lH NMR of the product
obtained. An un~xpected double doublet appeared at a3.69 (Fig.6, A). The
13C NMA showed only three quatemary carbon at a 146.31, 145.97, and
140.00. Two unexpected signals were observed at 0 80.90 and 54.13 (Fig.7, A).
Clearly, Ihe product obtained was not S6c. II was Ihe alcohol 55c. The signal at
a80.90 was due to the carbon bearing the hydroxyl <!-nd the two phenyl groups,
and the one at a54,13 due to the carbon 10 which was allached the len carbon
side chain. Further treatment of SSe with a stronger acidic catalyst, l.e., p.
toluenesulphonic acid (pTSA) in tolu~ne at reffux (Scheme 5) produced 1he
desired compound S6c. As expected, its 1H NMR spectrum showed a multiplet
at 3 2.43 accounting for the allylic methylene (Fig.G, B). Five signals at a 143.43,
142.93,142.40,141.00 and 136.92 were atso observed accounting lor the five
quaternary carbons in its 13C NMA spectrum (Fig.7, S).
This interesting result can be explained jf we compare the structure of the
substances 47a-d and 54a-c. An electron donating group is present on
compounds 47a-d, I.e., a methoxy group which can assist the dehydration
reaction (Scheme 6). Therefore, the compounds 54a-c without electron
donating group on their aromatic ring need a stronger acidic catalyst pTSA and
higher reaction temperalure to achieve the same reaction.
This result emphasizes that a very subtle change in reaction condition and
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the chemical slruclure of the substrate may drastically change the outcome of a
chemical reaction.
All new compounds were char~cterized by IR, 1H NMR, 13C NMR, MS
spectrum. All spectra were consistent with the assigned stnlctures. The final
platinum (II) complexes 40a-c also passed erement analysis (C, H, N).
Scheme 6
(CHZ)n-4OTIfP
]
n= 6(.), 8(b), lO(c), ll(d)
/47
H,C
48
30
Fig.6 1H NMR Spectra of Compounds SSc lA) and S6e (8).
A.
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Fig.7 13C NMA Spectra of Compounds SSe (A) and SSe (B).
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2.3 !n.Y!!rQ Antitumor Activity
Two human breast tumor cell lines were chosen baned on their estrogen
receptor content, to evaluate the anlilumor activities of our new platinum (t1)
complexes.71 The cytotoxicity of our compounds was lested along with controls
(cisplatin and tamoxifen) on both ER+ (MCF-7) and ER- (MOA-MD-231) human
mammary carcinomas in order to assess the potential selective anti-neoplastic
effect on hormone-dependent breast cancer. The antitumor activity was
evaluated with a colorimt'ltric assay that uses the ability of viable cells to reduca
a colorless tetrazolium salt 3-(4,5-dimethyllhiazol-2-yl)·2.5-diphenyltelrazolium
bromide (MIT), into a thiazolyl blue MIT formazan (Fig.8).72 A recent report
indicates that the MTT assay can be used to replace Ihe (3H] -uridine assay for
chemosensitivity screening. The colorimetric assay has the advantages of being
safer, less cos!Jy and simpler than Ihe radiometric assay.73 The MTT assay is
widely used now.74
Mitochondrial
Enzymes
MIT
{colorless}
MIT-FORJ\rIAZA1'I
(thiazolylblue)
Fig.S The Reaction Equation of MTr Reduction.
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As shown by the MIT assays on two human breast cancer cell lines, our
new compounds demonstrated cytotoxicity on both ER+ (MCF-7) and ER-
(MOA-MO-231) cells (Table 1). Clearly, the more lipophilic Ihe compound. Ihe
belter Ihe cytotoxicity. The compounds 40bM c without hydroxy groups showed
similar cytotoxicity to cispJatin and higher cytotoxicity than tamoxifen, particularly
on the MDA-MD-231 (EW) cell line. This result was and can be explained by the
following fashion;62 a more lipophilic compound could theoretically penetrate
the lipophilic calf membranes more easily, therefore concentrate sufficiently in
the cell to produce its biological activity.
Table ·1. Inhibitory concentration of drug on both
ER+ and EW breast cancer cell lines.
Drug \ Cell Line MCF-7 (ER+) MDA·MD-231 (EA-)
ICso (~M)a ICSO (~M)a
Cisplatin 3.1±0.3 2.4tO.2
Tamoxifen 11±1 28t3
39a 44±4 30±3
~;~ ~~:~ ~:~~-
39d 16±2 7.0±0.6
4Da 7.DtO.S 4.0±0A
40b 3.4tO.3 1.StO.2
40c 4.0+0.4 1.0tO.1
41 14±1 2.4±O.2
a. Concentrallon Inhlbltlng SO% of cell growth was
determined graphically from the cell survival curves
(Fig.9, 10). Data represent meanvalues±SD for
eight wens.
As we expected, platinum (II) complexes with a longer side chain has the
tendency to increase the cytotoxic activity. The compound 39d with eleven
carbon atoms side chain was significantly more cytotoxic as compared with
34
compounds 39a·c containing less carbon atoms. The reason might be as
described before: (1) a compound with a ronger side chain might allow the
platinum (II) complex portion to alkylate DNA more efficiently due to the fewer
steric interactions between the triphenylethylene moiety and DNA; (2) the
increase of carbon atoms in the side chain could increase the lipophilicity of the
compound, therefore might improve its cytotoxic activity.
The complexes 39a·d with two hydroxy groups showed cytotoxic activities
by inhibiling proliferation of the MCF·7 (EA+) cells, which appears not to be
mediated by {he EA. This seems to be the case since the proliferation of the
MDA·MD·231 (ER") cells was inhibited at a lower concentration as it was for the
inhibition of MCF-7 (EA+) cells. However, it is important to indicate that the
desired selectivily of the compounds 39a·d might be expressed more clearly
(and possibly only) in vivo as demonstrated previously for the compounds 32
and 33. The hypothesis of ER mediate selectivity of compnunds 39a·d should
be and will be further evaluated in vivo in the future.
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2.4 Conclusion.
In a conclll.""i':Jn, eight new platinum (II) complexes have been synthesized
and tested for their biological activities in vitro. The synthesis for these types of
compounds is straightforward and efficient. The lipophilic compounds 40b-c
showed promising antitumor activity for both ER+ and EA- human breast cancer
cells in vitro,
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Chapter 3
EXPERIMENTAL
3.1 Synthesis
3.1.1 General Procedures.
Anhydrous reactions were performed under an inert atmosphere, the set-
up assembled and cooled under dry nitrogen. Unless otherwise noled, starting
material, reactant and solvents were obtained commercially and were used as
such or purified and dried by standard means.75 Organic solutions were dried
over magnesium sulphate (MgS04), evaporated on a rotatory evaporator and
under reduced pressure. All reactions were monitored by UV fluorescence, or
staining with iodine or spraying with an aqueous solution of phosphomolybdic
acid followed by heating the plate around 135 0G. Commercial TLC plates were
Sigma T 6145 (polyester silica gel 60 A, 0.25mm). Preparative TLC was
performed on 1mm silica ga160 A, 20x20 plates (Whalman, 4861 840). Flash
column chromatography was perfvrmed according to the method of Slill and co-
workers on Merck grade 60 silica gel, 230·400 mesh.76 All solvents uSf'ld in
Chromatography had been distilled. Melting points were recorded on an
Electrothermal 9100 apparatus and are uncorrected. The infrared spectra were
taken on a Nicolet model 205 FT·IR, or Perkin Elmer model 2000 FT·rR
spectrophotometer. Mass spectral assays were obtained using a VG Micromass
7070 HS instrument using an Ionisation energy of 70 eV, Nuclear magnetic
resonance spectra were obtained in CDCl3 solullon, unless otherwise noled,
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on a General Electric GE 300-NB (300 MHz) instrument: chemical shifts were
measured relative to internal standards; tetramelhylsilane (TMS, S 0.0 ppm) lor
'H and CDCI3 (8 77.0 ppm) for 13C NMR. Multiplicities are described by the
following abbreviations: s (singlet), d (doublel), q (quartet), p (pentet), m
(multiplelj, dd (double doublet), tq ( triple quartet), and so on. The NMR
assignments were assisted by 13C_1H correlation (HET-CORR) 2-D spectra.
3.1.2 Conversion of Bromoalcohols to lodotetrahydropyranyl Ethers.
A. Synthesis of Hetrahydropyranyloxy-n·bromoalkane (43).
A solulion of bromoalcohol 42 (27.6 mmol), dihydropyran (2.57 9, 30.6
mmol), and pyrldlnium p-toluenesulfonate (PPTS) (10mg, 0.04mmol) In
dJchloromelhane (CH2CI2, 50 ml) was stirred for 5 hrs under nitrogen.
Afterwards, sodium bicarbonate (NaHCQ:), 500mg) and MgS04 (5.0 9) were
added to lhe reaclion mixture and stirred 15 minutes before being filtered on a
short pad of ceUle 1!i1ica gel (1 cm 14 em) using CH2CI2 as eluent. The filtrate
was evaporated to a viscous oil 43 (98% yield) which was used without further
purification in the next step.
1.Tetrahydropyranyloxy-S-bromohexane (43a)
IR, tlmax (thin film): 1170·1000 (C-O) cm-1; 'H NMR (& ppm): 4.57 (1H, t, J=3.2
Hz, ·QCti0-), 3.87,3.74,3.50, and 3.38 (4H, 4xm, -Gti20CHOC!::i2-), 3.41 (2H.
I, J=6,7 Hz, -ClliBr). 1.3-2.0 (14H, m, -Clli-): MS, mi.: 265 (M+ + 1), 163 (M+-
OTHP).
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1-Tetrahydropyranyloxy·S-bromooctane (43b) .
IR, "max (thin film): 1170-1000 (C-O) em-1; 1H NMR (6 ppm): 4.5B (1H, t, J:,3.5
Hz. -ecHO-I. 3.87, 3.73, 3.50 and 3.38 (4H, 4,m, -CIl20CHOCtl2-), 3.41 (2H,
I, J=6.B Hz, -Cti2Br), 1.2-2.0 (1BH, m, -C.!:::!.2-); MS (m/e): 293{M+ + 1), 191(M+-
OTHP).
1·Tetrahydropyranyloxy-10·bromodecane (43c)
IR, "max (thin film): 1170-1000 (C-O) em-1; 1H NMR (6 ppm): 4.58 (lH, I, ·J=3.5
Hz, -OCl:IO-), 3.87, 3.73, 3.50 and 3.38 (4H, 4,m, -Ctl20CHOCtl2-), 3.41 (2H,
I, J=5.8 Hz, -Ctl2Br), 1.2-2.0 (22H, m, ,CI:!2-); MS (mle): 321 (M++ 1), 219(M+-
OTHP).
1-T,,'ra"hydropyranyloxy·11·bromoundecane (43d)
lA, "max (Ihln film): 1170-1000 (e-O) cm-1; 1H NMA (6 ppm): 4.58 (1H, I, J=3.5
Hz, -oCI:!O-), 3.87, 3.73, 3.50 and 3.38 (4H, 4,m, oCIl20CHOCtl2-), 3.41 (2H,
I, J=5.8 Hz, -Ctl2B~, 1.2-2.0 (24H, m, oCtl2-); MS (mle): 335 (Mt + 1), 233(M+-
OTHP).
B. Synthesis of 1-letrahydropyranyloxy·n-iodoalkane (44).
Sodium locIide (6.07 g, 40.5 mmel) was added 10 a solulion of Ihe crude
bromide 43 (27mmoQ in dried acetone. The reacUen mixture was slirred al 23c..~
for 5 hrs. Then, most of the solvent was evaporated and the residue was
transferred to an extraction flask with ether (150 mll and waler (100 mL). The
organic phase was washed with water (6 X 50 mL), dried, filtrated and
concentrated to a viscous liquid. The crude iodide 44 (98% yield) was used as
such at the alkylation step.
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1-Tetrahydropyranyloxy-6-iodohexane (44a)
lA, \)max (thin fHm): 1170-1000 (C-O) cm-1; 1H NMR (0 ppm): 4.57 (1H, t, J=3.2
Hz, -OCHO·), 3.87, 3.74, 3.50 and 3.38 (4H, 4xm, -C.t!.20CHOC.t!.2-), 3,19 (2H,
I, J=7.0 Hz, -CH2'), 1.3-2,0 (14H, m, -C.t!.2-); MS (m/e): 311 (M+ - H), 211 (M+-
OTHP).
1-Telrahydropyranyloxy·8·iodooctane (44b)
IR, umax (Ihin film): 1170-1000 (C-O) cm·1; 1H NMR (0 ppm): 4.58 (1H, t, J=3.5
Hz, -OCliO-), 3.87, 3.73, 3.50 and 3.38 (4H, 4xm, -Cli20CHOCli2-), 3.19 12H,
t, J=7.0 Hz, -C.t!.2I), 1.2-2.0 (18H, m, -C!:!.2-); MS (m/e): 339 (M+ -H), 239 (M+-
OTHP).
1-Tetrahydropyranytoxy-1 O-iododeeane (44e)
lA, umax (thin film): 1170·1000 (C-O) cm-1; 1H NMR (o ppm): 4,58 (1 H, t, J=3.5
Hz, -OCliO-), 3.87, 3.73, 3.50 and 3,38 14H, 4xm, -C!:!20CHOC!:!2-), 3,19 (2H,
t, J=7.0 Hz, -C!:!2I), 1.2-2.0 122H, m, -C!:!2-): MS (m/e): 367 1M> - HI, 267 (M+-
OTHP).
1-Tetrahydropyranyloxy-11-iodoundecane (44d)
lA, umax (thin film): 1170-1000 (C-O)cm-1; 1H NMA (0 ?pm): 4,58 (1H, I, J=3.5
Hz, -OCliO-), 3.87, 3,73, 3,50 and 3.38 (4H, 4xm, -C!:!20CHOC!:!2-), 3.19 12H,
t, J=7.0 Hz, -C!:!2'), 1.2-2.0 124H, m, -C!:!2-): MS (mle): 381 IM+ - H), 281 (M+-
OTHP).
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3.1.3. Conversion of 8enzyl-4-Hydroxyphenyl Ketone to Bishydroxy
and Bismethoxy 'TrisphenylethyJene Platinum (II) Complexes
39a-d and 41.
A. Synthesis of benzyl-4-methoxyphenyl ketone (45).
Benzyl-4-hydroxyphenyl ketone (2.12 g, 10 mmol) and sodium hydroxide
(0.60 g, 15mmol) was dissolved in 250 ml ethanol by heating. The hoI solution
was added dropwise with dimethyl sulfate (1.51 g, 12 mmol). The reaction
mixture was refluxed for 4 hrs. After evaporation, the residue was diluted with
ether (200 ml) and washed with water (5x50 ml). The ethereal phase was
dried and evaporated to give a white powder which was purified by flash
column chromatography (hexane:acetone, 9:1). The yield was 80% average
(98% taking in consideration the starting material ketone recovered). mp: 76.2-
77.0 'C: IA. "max (KBr): 3090-3000 IAr-H), 1S80 IC=O), lS00 (C=C) em-': 'H
NMA (5 ppm): 7.98, 6.90 (4H, 2xd apparent, J=8.87 Hz, t! in para substituted
anisyl group), 7.30-7.21 (5H, m, Ar-.!:!l, 4.20 (2H, s, -Ct!2-), 3.80 (3H. s, -OC.!::!3);
13C NMA (0 ppm): 196.06, 163.37, 134.83, 130.79(2), 129.44. 129.25(2),
128.48(2),126.63,113.65(2),55.32,45.11. MS (m/e): 226 (M+), 135 (M+ -
CH2CSH5)'
B. Synthesis of 1-(4'-methoxyphenyl)-2-phenyl·n-tetrahydro-pyrapyloxy-
alkanone (46).
To a stirred suspension of sodium hydride (448 mg, 11.2 mmol, 60%
dispension in mineral oil) in 150 mL dry tetrahydrofuran (THF) the ketone 45
(2.30 g, 10.2 mmol) was rapidly added. The reaction mixture was heated (50
0C) with water bath for 1 hr under a nitrogen atmosphere. After cooling, 1-
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tetrahydropyranyloxy-n·iodoalkane 44 (11.2 mmol) was added dropwise and
the resulting mixture stirred overnight (18 hrs) at room temperature (23 0C).
Most of the solvent was then evaporated and the residue was diluted with ether
(200 ml) and treated with water (50 ml). The ethereal phase was washed
thoroughly with water (6x50 ml), dried and evaporated to give an oil which was
purifed by flash column chromatography (hexane:acetone, 95:5). The yield was
75% average (98% taking into account the alkyl iodide 44 recovered).
1-{4'-Methoxyphenyl}-2-phenyl-S-tetrahydropyranyJoxy-octanone (46a)
IR, "max (Ihin film): 3090-3000 (Ac-H), 2930-2860 (C-H), 1680 (C=O), 1600
(C=C) cm-1; 1H NMR (5 ppm): 7.95, 6.85 (4H, 2xd apparent, J=8.93 Hz,.tl. in
para substituted anisyl group), 7.32-7.14 (5H, r:n, Ar-til, 4.55 (1H, t, J=3.51 Hz,
-OCliO-), 4.49 (IH, I, J:7,25 Hz, -Cli-), 3,64, 3,69, 3.48, 3,34 (4H, 4xm,
-CI!20CHOC!i2-), 3,79 (3H, S, -OC!i3), 2,23-1.18 (16H, m, -C!i2-); 13C NMR
(6 ppm): 196.44, 163,12, 140,17, 130,82(2), 129,84, 126,69(2), 128,03(2),
126.73, 113.56(2),98.73,67.48,62.24,55.30,53.17,33.97, 30.70, 29.59,
29.40,27.62,25.99,25.42,19.60; MS (m1e): no M+, 326 (M+ - DHP), 239 (M+-
CSH100THP),
1-{4'-Methoxyphenyl)-2-phenyl-'a-tetrahydropyranyloxy-decanone (46b)
IR, "max (Ihin film): 3090-3000 (Ar-H), 2930-2880 (C-H), 1680 (C=O), 1600
(C=C) em-1; 1H NMR (5 ppm): 7.96,6.86 (4H, 2xd apparent, J=8.87 Hz, 1:1 in
para substituted anisyl group), 7.33-7.16 (5H, m, Ar-tl), 4.57 (1H, t, J=3.51 Hz,
-OCliO-), 4.49 (IH, I, J=7,24 Hz, -Clio), 3,86, 3,71, 3,50, 3,36 (4H, 4xm,
-CI!20CHOClf2-), 3,82 (3H, S, -OC!i3), 2,16-1,20 (20H, m, -C!i2-); 13C NMR
(6 ppm): 198,60, 163,18, 140,23, 130,91(2), 129,91,128,74(2), 128,09(2),
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126.75. 113.62(2). 98.80, 67.64. 62.33, 55.39. 53.24, 34.06. 30.75, 29.71,
29.56.29.36(2),27.75,26.17,25.48,19.66. MS (mle): no M+, 354 (M+· OHP),
239 (M+· C7H140THP).
1-(4'-Methoxyphenyl)-2-phenyl-12-tetrahydropyranyloxy-dodecanone (46c)
lA, umax (thin film): 3090·3000 (Ar-H), 2930-2860 (e-H), 1680 (C=O). 1600
(C=C) em-'; lH NMR (0 ppm): 7.96, 6.84 (4H, 2xd apparent. J=B.8S Hz,!:::i in
para substituted anisyl group), 7.33-7.16 (5H, m, Ar-til, 4.57 (1 H, I, J=3.51 Hz,
-OCtiO-), 4.50 (lH.t. J=7.24 Hz. -Cti-). 3.86.3.72.3.48.3.37 (4H. 4xm,
-C!:i20CHOC!:i2-). 3.76 (3H. s.-OC&). 2.16-1.20 (24H, m, -C!:i2-); 13C NMA
(S ppm); 198.36. 163.03. 140.14, 130.74(2). 129.74. 128.59(2). 127.94(2).
126.62,113.45(2),98.62,67.47,62.12,55.15,53.08, 33.95, 30.62, 29.59,
29.47,29.35(2),29.27(2).27.60,26.08.25.34,19.53; MS (m1e): no W. 382 (W
- DHP), 239 (M+- C9H,80THP).
1-(4'-MethoxyphenyJ}2-phenyl-13-tetrahydropyranyloxy-tridecanone (46d)
IA. "max (thin film): 3090-3000 (Ar-H), 2930-2860 (C-H). 1680 (C=O). 1600
(C=C) em-'; lH NMR (0 ppm): 7.96, 6.87 (4H, 2xd apparent, J=B.94 Hz,.t!. in
para substituted anisyl group), 7.32-7.1 (5H, m, Ar-ttj, 4.57 (1H, I, J=3.51 Hz,
·oc.t!o·), 4.49 (1H, I, J=7.25 Hz, -C.!:::!:), 3.86, 3.72, 3.4B, 3.37 (4H, 4xm,
-C!:i20CHOC!:i2-), 3.81 (3H. s, -OC&), 2.19-1.17 (26H. m. -C!:i2-); 13C NMA
(S ppm): 198.61. 163.18. 140.26. 130.90(2). 129.98. 128.74(2). 128.12(2).
126.78.113.65(2).98.82,67.67.62.33.55.39,53.26. 34.09, 30.79,29.74,
29.61,29.55(4).29.46(2). 27.77. 26.23, 25.51; MS (m/e): no M+. 396 (W-
DHP), 225 (W - C,1 H220THP).
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C. Synthesis of x-phenyl-y,y-bis{4'-methoxyphenyl)-x·alken-1-o1 (48).
A Grign...rd reagent, ~methoX)'Phenyl magnesium bromide was prepared
from magnesium (432 mg, 18.0 mmol) and 4-methoxyphenylbromide (2.81 g,
15.0 mmoQ in the presence of a crystal of iodine in 100 ml of dry ether. The
Grignard reagent was usually ready after stirring at room temperature (23 Oe)
overnight (18 hrs), but sometimes required healing at reflux to initiale the
reaction. A solution of the ketone 46 (3.0 mmol) in dry ether was treated with
the excess of the Grignard reagent for 6 hrs under nitrogen at room temperature
(23 OC) and was then hydrolysed with 50 mL of 10% aqueous ammonium
chloride. The ether phase was washed with water (5 x 50 mL), dried and
evaporated to give the crude tertiary alcohol intermediate 47. The oily residue
refluxed with 95% ethanol in the presence of pprS (100 mg, 0.40 mmol) for 8
hrs. After evaporation of the solvent, the residue was laken with ether. The
ethereal phase was washed with water (5 x 50 mL), dried and evaporated to an
oil. Aash column chromatography (hexane:acetone, 7:1) gave a pure 48 in 85%
average yield as a viscous oil.
7·Phenyl-8,8-bis(4'·I;;~thoxyphenyl)-7.oQCte~1-o1 (48a)
lA, umax (thin film): 3340 (br, OH), 3090-3000 (Ar-H), 2930-2860 (C-H), 1600
(C=C) cm-1; 1H NMR (6 ppm): 7.18-7.05 (7H, m, Ar-W, 6.87 (2H, d apparent,
J=8.72 Hz, l:i in para substituted anisyl group), 6.77, 6.53 (4H, 2xd apparent,
J=8.82 Hz, l:i in parp substituted anisyl group), 3.82, 3.66 (6H, 2xs, 2x-QCl:::ia),
3,55 (2H, I, J=6,60 Hz, ,CJj20H), 2,43 (2H, m, ·C=C·C~·), 1,65 (1H, brs, ·OJj),
1.50 (2H, p, J=7,30 Hz, ·C~CH20H), 1,30·1.10 (6H, m, ·(C~)3·); 13C NMR
(0 ppm): 158.16, 157.37, 142.87, 139.73, 138.06, 136.25, 135.73, 131.84(2),
130,56(2),129,54(2),127.80(2),125.85, 113,39(2), 112,66(2),62,91,55,18,
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54.95, 35.85, 32.60, 29.42, 28.82,25.32; MS (m/e): 416 (M+). 329 (M+-
C5H'00H).
g·Phenyl-10,1O-bis(4'-methoxyphenyl)-9-decen-1 ~ol (48b)
IR, "max (thin film): 3340 (br, OH), 3090-3000 (Ar-H), 2930-2860 (C·H), 1600
(C=C) cm-1; 1H NMR (15 ppm): 7.18·7.05 (7H. m, Ar-l::±), 6.88 (2H, d apparent,
J;;8.73 Hz, l::± in para substituted anisyl group), 6.77, 6.54 (4H, 2xd apparent,
J;;8.83 Hz, J::i in para substituted anisyl group). 3.82. 3.67 (6H, 2xs, 2x-OC!:i3),
3.60 (2H, t, J=6.63 Hz, -Clf20H), 2.43 (2H, m, -C=C-Clf2-), 1.64 (IH, brs, -elf),
1.51 (2H, p, J=7.30, -Clf2CH20H), 1.30-1.10 (10H, m, -(Ctf2)5-); 13C NMR (0
ppm): 158.12, 157.31, 142.91, 139.85, 137.94, 136.28, 135.77. 131.85 (2),
130.56(2),129.55(2),127.78(2),125.81, 113.37(2), 112.63(2), 63.00, 55.19,
54.95,35.91,32.69,29.58,29.22,29.15,28.85,25.61; MS (m1e): 444 (M+), 329
(M+ - C7H,40H),
11-Phenyl-12,12-bls(4'-methoxyphenyl)-11~dodecen-1-o I (48c)
IR, "max (thin film): 3340 (br, OH), 3090-3000 (Ar-H), 2930-2860 (C-H), 1600
(C=C) em-1; 'H NMR (B ppm): 7.18-7.05, (7H, m, Ar-lf), 6,87 (2H, d apparent,
J;;a.72 Hz, .l:i in para substituted anisyl group), 6.77, 6.53 (4H, 2xd apparent,
J;;8.80 Hz, .Ii in para substituted anisyl group), 3.81, 3.66 (6H. 2xs, 2x-QCti3),
3,61 (2H, t, J=6,62 Hz, -Clf20H), 2.42 (2H, m, -C=C-Clf2-), 1.66 (IH, bro, -Otl),
1.53 (2H, p, J=7.20 Hz, -Ctf2CH20H), 1,38-1,10 (14H, m, -(Ct!217-); 13C NMR
(B ppm): 158.10, 157.29, 142.89, 139.89, 137.88, 136.27, 135,80, 131.84(2),
130.57(2),129.53(2),127.75(2),125,78. 113.34(2), 112.62(2),62.95,55.15,
54.92,35.91,32.71,29.65,29.48, 29.35(2). 29.20, 28.87, 25.68; MS (mJe): 472
(W), 329 (M+ - C9HI80H).
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12-Phenyl-13,13-bis(4'-methoxyph enyl)·12·tridecen-1-o1 (48 d)
lA, vmax (thin film): 3340 (br, OH), 3090-3000 (Ar-H), 2930-2860 (C·H), 1600
(C:=C) em-1; 1H NMA (li ppm): 7.16-7.09, (7H, m, Ar-!:i), 6.87 (2H, d apparer.I,
J=8.87 Hz, J::i in para substituted anisyl group), 6.n, 6.54 (4H, 2xd apparent,
J:=8.82 Hz, tl in para substituted anisyl group), 3.62, 3.67 (6H, :2X5, 2x-QC.!±3),
3.63 (2H, t, J=6.62 Hz, ·CI:i20H), 2.42 (2H, m, ,C=C,CI:i2'), 1.69 (1H, br S, ·Ol:i),
1.53 (2H, m, -C!:i2CH20H), 1.39·1.10 (16H, m, ,(C!:i2)8'); 13C NMR (6 ppm):
158.10, 157.33,142.92, 139.92, 137.89, 1~6.30, 135.84, 131.87(21, 130.60(2),
129.55(2),127.79(2),125.79,113.36(2),112.66(2), 63.06, 55.20, 54.97, 35.94,
32.75,29.71, 29.49(3), 29.39, 2!i.25, 28.90, 25.70; MS (m1e): 486 (M+), 329 (M+
• C10H200H).
0_ SynthesIs of 1-bromo-x-phenyl·y,y-bis(4'-methoxyphenyl)-x-alkene (49).
A solution of the alcohol 48 (2.25 mmol), carbon tetrabromide (2.98 9, 9.00
mmol) and triphenylphosphine (2.36 g, 9.00 mmol) in dry ether (100 mL) was
stirred at room temperature (23 OC) for 24 hI'S under a nitrogen atmosphere. The
triphenylphosphine oxide precipitale was fillrated and the resulting solution was
washed thoroughly with water (5x25 mL), dried and evaporated to an oil. The
crude material was purified by flash column chromatography (hexane:acetone,
95:5) to give the bromide 49 in 85% yield.
1-Bromo-7-phenyl·8,8-bls(4'~melhoxyphenyl)-7-octene(49a)
lA, umax (thin film): 3090-3000 (Ar-H), 2930·2860 (C-H), 1600 (C:=C) cm-1; 1H
NMA (li ppm): 7.18-7.05 (7H, m, Ar-W, 6.88 (2H, d apparent, J=8.73 Hz, H in
para subsliluted anisyl group), 6.n, 6.53 (4H, 2xd apparent, J:=8.81 Hz, H in
para subsliluted anisyl group), 3.82, 3.66 (6H, 2X5, 2X-OC!:i3), 3.32 (2H, t,
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J=6.86 Hz, ,C!i2Br), 2.43 (2H, m, ,C=C,C!i2'), 1.74 (2H, p, J=7.30 Hz,
,C!i2CH2Br), 1.40·1.18 (6H, m, ·(C!i2I3'); 13C NMR (~ppm): 158.23, 157.40,
142.81, 139.59, 138.20, 136.20, 135.69, 131.84(2), 130.54(2), 129.54(2),
127.84(2), 125.89, 113.43(2), 112.67(2), 55.20, 54.96, 35.77, 33.91, 32.62,
28.75,28.65,27.80; MS [mle): 478 (M+), 480 (M-+- + 2),329 (M+ - CSH1OBr).
'-Bromo-g·phellyl-10,10-bis(4'·methoxyphenylj-9-decene (4gb)
lA, umax (thin film): 309Q.3000 (Ar-H). 2930·2860 (C·H), 1600 (C=Cj em-'; 'H
NMA (8 ppm): 7.18-7.05 (7H, m, Ar-.!:!), 6.88 (2H, d apparent, J=B.S9 Hz, tl in
para SUbstituted anisyl group), 6.77, 6.54 (4H, 2xd apparent, J=B.69 Hz, li in
para substituted anisyl group), 3.82, 3.67 (6H, 2xs, 2x-QC!:i3), 3.37 (2H, I,
J=6.86 Hz, ,C!i2Br). 2.43 (2H, m, ·C=C·C!i2·), 1.80 (2H. p. J=7.33 Hz.
-C!i2CH2Br), 1.42-1.10 (10H, m, ,(C!i2)5'); 13C NMR (8 ppm): 158.14, 157.33,
142.89, 139.78, 137.99, 136.25, 135.77, 131.86(2), 130.57(2;, 129.55(2),
127.80(2),125.83, 113.37(2), 112.65(21. 55.19, 54.94, 35.B9, 34.03,32.74,
29.52,29.00, 2B.80, 28.56, 2B.05. MS (mle): 506 (M+), SOB (M' + 2), 329(M+ •
C7H14Br).
1·Bro~o·11-phenyl·'2.12·bls( 4'·melhoxyphenyl)-11·dodecene (49c)
IR, umax (Ih.n Ijlm): 3090·3000 (Ar·H), 2930·2860 (C·H), 1600 (C=C) em·1; 'H
NMR (0 ppm): 7.16-7.05 (7H, m, Ar-J::l), 6.87 (2H, d apparent, J==e.77 Hz, l:t in
para substituted anlsyl group). 6.77, 6.53 (4H, 2xd apparent, J=8.84 Hz, tl in
para substituted anisyl group), 3.80, 3.64 (6H, 2xs, 2x·QC.I:i3), 3.37 (2H, I,
J=6.87 Hz, ,C!i2Br), 2.43 (2H, m, ,C=C,C!i2'), l.B2 (2H, P, J=7.32 Hz,
-C!i2CH2Br), 1.40·1.10 {14H, m, -(Ctl217'); 13C NMR (; ppm): 158.10, 157.30,
142.86, 139.80 137.92, 136.21, 135.73, 131.82(2), 130.54(2), 129,51(2),
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127.74(2), 125.77, 113.31(2), 112.60(2), 55.11, 54.88, 35.89, 33.97, 32.74,
29.61, 29.30{2), 29.15, 28.83, 28.66, 28.09; MS (mle): 534 (M+), 536 (M+ + 2),
329 (M+· CgH16Br).
1-Bromo-12-phenyl-13,13-bis(4'-methoxyphenyIH2-tridecene (49d)
IR, umax (thin lilm): 3090-3000 (Ar-H), 2930-2860 (C-H), 1600 (C=C) em- l ; 1H
NMR (0 ppm): 7.18-7.08 (7H, m, At-W, 6.87 (2H, d apparent, J::8.71 Hz. J::l. in
para subslltuled anlsyl group), 6.77, 6.54 (4H, 2xd apparent, J=8.77 Hz, ti in
para subsliluted anisyl group), 3.82, 3.67 (6H, 2xs, 2x-OCI:I.3), 3.39 (2H, I,
J=6.86 Hz, -C!:l2Br), 2.42 (2H, m, -C=C-CJ:l2-), 1.84 (2H, P, J=7.34 Hz,
-CJ:l2CH2Br), 1.40-1.10 (18H, m, -(C!:l2)8-); 13C NMR (8 ppm): 158.14, 157.33,
142.94, 139.88, 137.92, 136.26, 135.81, 131.87(2), 130.60(2), 129.56(2),
127.75(2), 125.80, 113.36(2), 112.66(2),55.17,54.98,35.91, 34.02, 32.79,
29.6B, 29.44(2), 29.38, 29.21, 28.90, 28.71, 28.13; MS (mle): 548 (M+), 550 (M+
+ 2), 329 (M+ - ClOH20Br).
E. Synthesis of 1-[(2'-amlnoethyl)amino]-x·phenyl-y,y-bls(4'-methoxy·
phenyl) -x-alkene (50).
Under a nitrogen atmosphere, ethylenediamine (900 mg, 15.0 mmol) was
added to a solution of the bromide 49 (1.50 mme!) in 80 mL of dry methanol.
After boiling for two days under reflux (sometimes longer reaction period was
requIred), the solvent was evaporated. The resulting residue was dissolved In
ether (150 mL) and washed with a solution of NaHC03 (30 mL, 5% aqueous)
and with water (5x30 mL). The ethereal phase was dried and evaporated to a
viscous oil 50. The yield was 90%.
50
1-[(2'-Aminoethyl)aminol·7.phenyl-a,S-bis(4'-methoxyphenyl}-7-oclene (SOa)
JA, \lmax (thin film): 3340 (bT, N-H), 3090-3000 (Ar-H), 2930-2860 (C-H), 1660
(N-H, bending), 1600 (C;C) cm-1; 1H NMR (0 ppm): 7.18-7.05 {7H, m, Ar-W,
6.S7 (2H, d apparent, J;8.65 Hz, tl in para substituted anisyl group), 6.77, 6.53
(4H, 2xd apparent, J=8.75 Hz, .I::i in para substituted anisyl group), 3.82, 3.67
(6H, 2xs, 2x-QC!:i:3), 2.79, 2.64 (4H, 2xt, J=5.92 Hz, -NHC.l::i2CH.2NH2), 2.54
(2H, I, J~7.25 Hz, -C~2NH-), 2.43 (2H, m, -C=C-Cfu-) 1.78 (3H, br s, -N~- and
-N~2), 1.43-1.18 (8H, m, -ICfu)4-); 13C NMR ('ppm); 158.14, 157.33,142.88,
139.76, 137.99, 136.23, 135.73, 131.64(2), 130.55(2), 129.53(2), 127.78(2),
125.81,113.3712),112.63(2), 55.16, 54.93, 52.42, 49.74, 41.58, 35.66,29.90,
29.60, 28.86, 26.99; MS (mle): 458 (M+), 428 (M+ - CH2NH2), 415 IM+ -
CH2CH2NH), 329IM+ -C5HlONHCH2CH2NH2).
1-[(2'·Amlnoethyl)amino]-g·phenyl-10,1D-bis(4'-methoxyphenyl)-9-decene
(SOb)
IR, Umax (Ihin film): 3340 (b., N-H), 3090-3000 (Ar-H), 2930-2860 IC-H), 1660
(N-H, bending), 1600 (CmC) cm-1; 1H NMA (0 ppm): 7.18-7.05 {7H, m, Ar-W,
6.88 (2H, d apparent, J=8.70 Hz, tl In para substituted anisyl group), 6.77, 6.54
(4H, 2xd apparent, J=8.83 Hz, H. in para substituted anisyl group), 3.82, 3,67
(6H, 2xs, 2x-OC&), 2.80, 2.65 (4H, 2X1, J~5.85 Hz, -NHCfuCfuNH2), 2.57
(2H, I, J~7.24 Hz, -C~2NH-), 2.42 (2H, m, -C:C-Cfu-), 1.50 (3H, brs, -N~- and
-Nfu), 1.46-1.10 1'2H, m, -(CfuJ6-); 13C NMR (S ppm): 158.10, 157.33,
142.90, 139.85, 137.95, 136.26, 135.80, 131.87(2), 130.57(2), 129.54(2),
127.1712), 125.79, 113.34(2), 112.62(2),55.17,54.94,52.61,49.53,41.76,
35.92, 30.11, 29.64, 29.41, 29.21,28.88,27.27: MS (mle): 486 (W), 456 (M+-
CH2NH2), 443 (W - CH2CH2NH), 3291M+ - C7H14NHCH2CH2NH2).
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1.C(2'.Aminoethyl)aminoJ·11·phenyl-12,12·bis(4'-methoxyphenyl)-11-
dodecene (50c)
IR, "max (thin film): 3340 (br, N·H), ·.lU90-3000 (Ar·H), 2930-2860 (C-H), 1660
(N-H, bending), 1600 (C=C) em-1; 1H NMA (0 ppm): 7.18-7.05 (7H, m, Ar-.l:::!),
6.87 (2H, d apparent, J=8.67 Hz, tI. in para substituted anisyl group), 6.77, 6.53
(4H, 2xd apparent, J=8.81 Hz, ti in para substituted anisyl group), 3.81, 3.66
(6H. 2xs, 2,-OCl:!3), 2.63. 2.69 (4H. 2'1, J=5.90, -NHC!:I2CfuNH2). 2.60 (2H, I,
J=7.27 Hz, .CI:!2NH-), 2.53 (3H. br s. -NI:!- and -NI:!2), 2.42 (2H, m. -C=C-C!:I2-),
1.48-1.10 (16H. m, -(CI:!2)6-); 13C NMR (6 ppm): 158.06. 157.26, 142.86.
139.82,137.84,136.20,135.73.131.80(2), 130.52(2). 129.49(2). 127.71(2),
125.74,113.28(2).112.57(2),55.09,54.87.51.98, 49.69. 41.27, 35.88. 29.80,
29.64,29.44(3).29.21.28.85.27.25. MS (mle): 514 (W), 484 (M+ - CH2NH2),
471 (M+ -CH2CH2NH), 329 (W - C9H,8NHCH2CH2NH2).
1-[(2'-Aminoethyl)amlno]-12-phenyl·13,13-bls(4'-methoxyphenyl)-12-
trideeene (SOd)
IR, "max (thin film): 3340 (br, N-H), 3090-3000 (Ar-H), 2930-2860 (C-H), 1660
(N-H. bendIng), 1600 (C=C) em- l ; 'H NMR (6 ppm): 7.16-7.08 (7H. m, Ar-I:IJ.
6.87 (2H, d apparent, J=8.62 Hz,l::I. in para substituted anisyl group), 6.77, 6.53
(4H, 2xd apparent, J=8.73 Hz, .1::::1. in para substituted anisyl group), 3.82, 3.67
(6H, 2xs, 2,-OCl:!3), 2.81, 2.66 (4H. 2xl. J=5.87, -NHCH2CI:!2NH2), 2.60 (2H, I.
J=7.23 Hz. -CI:!2NH-), 2.42 (2H. m. -C=C,C!:I2-), 1.51 (3H. brs, -NI:!- and -NI:!2),
1.48-1.10 (18H. m, -(CI:!2)g-); 13C NMR (6 ppm): 158.06. 157.29, 142.89,
139.85,137.84. 136.24. 135.77, 131.84(2). 130.57(2), 129.53(2). 127.72(2).
125.75.113.31(2),112.59(2).55.13,54.91,52.51. 49.89. 41.68. 35.90, 30.10,
29.66. 29.52(4). 29.23. 28.87, 27.32. MS (mle): 528 (M+). 498 (M+ - CH2NH2),
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F. Synthesis of 1-[(2'·aminoethyl}aminoJ-x-phenyl-y,y-bis(4'-hydroxy-
phenyl) -x-alkene (51).
A solution of 50 (0.665 mmol), in dry CH2CI2 (30 ml) was treated with a
solution of boron tribromide (1M in CH2CI2, 1.60 ml, 1.60 mmol) at -60 ec,
under nitrogen atmosphere. After the addition, the reaction mixlure was allowed
to warm at a room temperalure (23 OC) and was stirred for 18 hrs. The mixture
was refluxed during 2 hrs, then cooled down with an ice bath before adding 10
mL methanol. The resulting solution was adjusted wilh saturated NaHC03
solution to pH=7, then evaporated to 2-3 mL, treated with saturated NaHCOa
solution (30 mL), and extracted with ethyl acetate (5x30 mL). The crude yield is
around 60-80%. The product 51 was used wilhout further purification in the next
step. We obtained the following three compounds:
1-[(2'-AmInoethyl)amino}-7-phenyl-a,a-bis(4'-hydroxyphenyl}-7-octene (51a)
1-[(2'-AmlnoethyJ)amlno]-9-phenyl-l0,1()4,is(4'-hydroxyphenyl)-9-decene
(51 b)
1-[(2'-Aminoethyl)amlno]-11-phenyl-12;12-bis(4'-hydroxyphenyl}-ll-
dodecene (51c)
1-[(2'·Amlnoethyl)amlnoH2-phenyl-13,13-bis(4'·hydroxyphenyl)-12-
tridecene (51d)
G. Synthesis of 1-{cis-((2'-aminoethyl)amino]dichloroplatinum (1I)l-x-
phenyl-y,y-bis{4'-hydroxyphenyl)-x-alkene (39).
A solution of potassium tetrachloroplatinate (II) (219 mg. 0.528 mmol) in
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7.5 ml of a mixture of DMF and water (2:1) was added to a warm (35 0C)
solution of the diamine 51 (0.528 mmol) in 5 mL of DMF. The resulting mixture
(pH=9-10) was stirred in the dark for 2-3 days unlillhe pH value reached 4-5.
Then, one drop of N,N·dimelhylsulfoxide was added and the stirring was
continued for 2 hrs. The solvent was evaporated and the residue was
suspended in saturated potassium chloride solution (30 mL). A vigourous
stirring was essential in order to pulverized the lumps of platinum (II) complex
39. The resulting suspension was filtered, washed with water (100-250 mL),
and dried in a desiccator. The product can be further purified either by flash
column chromatography or by preparative TLC (CH2CI2:CH30H, 95:5). The
crude yield was around 80%.
1-{Cls-[(2'-amlnoethyl) amino] dichloroplalinum (1I)}-7-phenyl-a,a-bis(4'-
hydroxyphenyl)-7-octene (39a)
mp> 138 'C (dec.); lA, umax (KBr): 3400-3100 (O-H, N-H), 2930-2850 (C-H),
1600 (C=C) cm-1; 1H NMR (acetone-d6, appm): 8.32, 8.09 (2H, 2xbr s, 2xAr-
OW, 7.20-7.10 (5H, m, Ar-ti), 7.07, 6.B6 (4H, 2xd apparent, J=8.52 Hz,!:i in
para substituted phenol), 6.71, 6.48 (4H, 2xd apparent, J=8.62 HZ,!:i in para
substituted phenol), 5.68, 5.11, 4.98 (3H, 3xbr s, ·NtL- and ·N.t:(2), 3.21, 3.06,
2.77,2.67 (6H, 4xbr S, -C!::!2NHCJ:!2CI:l2NH2), 2.46 (2H, m, -C=C-C!::l2-), 1.78,
1.56 (2H, 2xbr S, -Cli2CH2NH-), 1.40-1.10 (6H, m, -(0!::l2)3-); 130 NMA
(acetone-de, 0 ppm): 156.88, 151i.07, 143.94, 139.72(2), 135.93, 135.62,
132.62(2),131.30(2),130.41(2),128.07(2), 126.55, 115.73(2), 114.93(2), 56.12,
53.42,47.78,36.33,27.64,26.82 (N.B. 2 carbons are hidden by acetone). Anal.
ealed. for C2SH34CI2N202Pt·11/5H20: C 45.68, H 5.26, N 3.80; found: C
45.72, H 5.28, N 3.70.
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1-{Cis-({2'-aminoethyl)amlno]dichloroplatinum (lJ)}-g-phenyf-l0,10-bis(4'-
hydroxyphenyl)-9-decene (39b)
mp> 138 °C (dec.); lA, 'Umax (KBr): 3400-3100 (O-H, N-H), 2930-2850 (C·H),
1600 (C=C) cm-1; 1H NMR (acetone-de, l) ppm): 8.35, 8.13 (2H, 2xbr 5, 2xAr-
Oill, 7.20-7.10 (5H, m, Ar-t!.), 7,07, 6.86 (4H, 2xd apparent, J=8.54 Hz. t! in
para substituted phenol), 6.71, 6,48 (4H, 2xd apperant, J=8.S2 Hz, tl in para
substituted phenol), 5.71, 5.10, 4,99 (3H, 3xbr 5, -Nti- and -N!:i2), 3.24, 3.05,
2.80,2.72 (6H, 4'br S, ·C!i2NHCt!2Ct!2NH2), 2.45 (2H, m, -C=C-Cl:!2-), 1.80,
1.58 (2H, 2xbr S, -Ct!2CH2NH-) 1.40-1.10 (10H, m, -(Cl:!2)S-); 13C NMA
(acetone-os, appm): 156.89, 156.08, 144.04, 139,86, 139.66, 135.95, 135.61,
132.59(2), 131.29(2), 130.39(2), 128.56(2), 126.55, 115.68(2), 114.94(2), 56.15,
53.51, 47.83, 36.46, 27.82, 27.21 (N.B. 4 carbons are hidden by acetone). Anal.
calcd. for C30H3SCI2N202Pt'2H20: C 47.37, H 5.57, N 3.68; found: C 47,40, H
5.62, N 3.73.
1-{Cis-((2'-amlnoethyl)amino]dlchloroplatinum (1I)H'-phenyl-12,12-bis(4'-
hydroxyphenyl)-"-dodeeene (3ge)
mp> 136 'C (dec.); lA, umax (KBr): 3400-3100 (D-H, N-H), 2930-2650 (C-H),
lS00 (C=C) em-1; 'H NMR (acetone-de, appm): 8,31, 8.09 (2H, 2xbr 5, 2xAr-
OJ:l.), 7.20-7.10 (5H, m, Ar-tl.), 7.07, 6.85 (4H, 2xd apparent, J=8.50 Hz,.Ii in
para substituted phenol), 6.71, 6.48 (4H, 2xd apparent, J=8.62 Hz, .I:f. in para
substituted phenol), 5.70, 5.08, 4.98 (3H, 3xbr 5, -Nt!- and ·N.l:i2), 3.25, 3.08,
2.78, VO (6H, 4xbr S, -Ct!2NHCt!2C!i2NH2), 2.45 (2H, m, -C=C-C!i2-), 1.82,
1.60 (2H, 2xbr S -Cl:!2CH2NH-), 1.40-1.10 (14H, m, -(Cl:!217-); 13C NMA
(acetone-dS, appm): 156.80, 155,95, 143,94, 139.75. 139.55, 135,85, 135.50,
132.47(2), 131.17(2), 130.27(2), 126.43(2), 126.44, 115.54(2), 114.82(2), 56.04,
55
53.38,47.71, 36.38,27.72,27.14 (N.B. 6 carbons are hidden by acetone). Anal.
calcd. for C32H42CI2N202Pt'2H20: C 48.73, H 5.88, N 3.55; found: C 48.65, H
5.78, N 3.61.
1-{Cls-[(2'-aminoethyl)amino]dichloroplatinum (1l)}-12-phenyl-13,13-bis(4'-
hydroxyphenyl)-12-tridecene (39d)
mp> 138 0C (dec.); lA, \Jmax (KBr): 3400-3100 (O-H, N-H), 2930·2850 (C-H),
1600 (C=C) em·1; 1H NMA (acetone-d6, 0 ppm): 8.31, 8.08 (2H, 2xbr s, 2xAr-
Oti), 7.20-7.10 (5H, m, Ar-tl), 7.07, 6.85 (4H, 2xd apparent, J=8A7 Hz,.!:::!. in
para substituted phenol), 6.71, 6.49 (4H, 2xd apparent, J=8.54 Hz, .I::::!. in para
substituted phenol), 5.70, 5.09, 4.97 (3H, 3xbr s, -N.!:::!.- and ·N!:!2), 3.28, 3.08,
2.75 (6H, 3xbr S, ·G!i2NHG!i2GH2NH2), 2.45 (2H, m, -G:G-Cli2-), 1,84, 1.62
(2H, 2xbr s -C!:!.2CH2NH-), 1.40-1.10 (16H, m, -(C.!:i2)S-); 13C NMA (acetone-
d6,6 ppm): 157.46, 156.63, 144.51, 140.43, 140.20, 136,51, 136.17, 133.14(2),
131.84(2),130.94(2),129.10(2),127.13, 116.20(2), 115.49(2),56.71,54.04,
4S.37, 37.06, 28.39, 27.82 (N.B. 7 carbons are hidden by acetone). Anal. calcd.
for C33H44CI2N202Pt'2H20: C 49.38, H 6.03, N 3.49; found: C 49.32, H 6.08,
N 3.52,
H. Synthesis of 1-(Cis-[(2'·aminoeth:tJ)amlnoldichloroplatinum (1I)J-12-
phenyl-13, 13·bis(4'-methoxyphenyl)·12-tridece:le (41).
The Platinum (II) complex 41 was obtained following the procedure of 39
takIng SOd as the starting malerial. The crude yield was around 80"10. The
product can be fUither purified either by flash column chromatography or by
preparative TLC (CH2CI2:CH30H, 98:2). mp > 173 DC (dec.); lA, tlmax (K8r):
3340 (br, N-H), 3090-3000 (Ar-H), 2930-2860 (C-H), 1600 (G=G) em-I; 1 H NMR
56
(0 ppm): 7.16-7.08 (7H, m, Ar-!:i), 6.86 (2H, d ~pparent, J=8.62 Hz, t:!. in para
substituted anisyl group), 6.76, 6.53 (4H, 2xd apparent, J=8.73 Hz. l:i in para
substituted anisyl group), 5.65. 5.05, 4.92 (3H, 3xbr s, -Nt!: and -Nl:i2), 3.80,
3.66 (6H, 2xs, 2x-OC!i3), 4.05, 3.18, 2.95, 2.75 (6H, 4xbr s,
-CJ::i2NHCl::!.2Ct!2NH2), 2.43 (2H, m, -C=C-C!:::!2-), 1.75, 1.52 (2H, 2xbr s,
-Cl:!.:1CH2NH-), 1.40-1.06 116H, m, -(Cli2)8-); l3C NMA IS ppm): 158_15,
157.34, 142.93, 139.90, 137.93, 136.28, 135.81, 131.88(2), 130.61(2),
129.58(2),127.80(2),125.83,113.40(2),112.67(2), 55.45, 55.22, 54.98, 53.47,
46.93, 35.98, 29.78, 29.55(2), 29.45, 29.34, 29.24, 28.97, 27.41, 26.56. Anal.
calcd. for CSSH48C12N202Pl: C 52.B9, H 6.09, N 3.52; found: C 52.83, H 6,06,
N3.51.
3.1.4 Conversion of Desoxybenzoin to Triphenylethylene Platinum
(II) Complexes 40a-c.
A. Synthesis of 1,2-blsphenyl-n-tetrahydropyranyloxy·alkanone (53).
Oesoxybenzoin 52 (2.00 g, 10.2 mmol) was rapidly added to a stirred
suspension of sodium hydride (448 mg, 11.2 mmol, 60% dispension in mineral
oil) in 150 mL dry tetrahydrofuran (THF). The reaction mixture was heated (50
0C) with water bath for 1 hr under a nitrogen atmosphere. After cooling, 1-
tetrahydropyranyloxy-n-iodoalkane 44 (11.2 mmol) was added dropwise and
the resulting mixture stirred overnight (18 hrs) at room temperature (23 °C).
Most of the solvent was then evaporated and the residue was diluted wilh elher
(200 mL) and treated with water (50 mL). The ethereal phase was washed
thoroughly with water (6x50 mL), dried and evaporated to give an oil which was
5,
purified by flash column chromat09raphy (hexane:acetone, 98:2). The yield was
75%, average (98% laking inlo account the alkyl iodide 44 recovered).
1,2-Bisphenyl-S-tetrahydropyranyloxy-octanone (53a)
lA, umax (thin film): 3092-3025 (Ar-H), 2933-2858 (C-H), 1683 (C=O), 1585
(C=C) em- l ; 'H NMR (6 ppm): 8.01-7.15 (10H, m, Ar-Il), 4.55 (lH, I, J=3.55 Hz,
-OCliO-), 4.53 (1 H, t, J=7.21 Hz, -C.l::!-), 3.84, 3.70, 3.47, 3.34 (4H, 4xm,
-CI:!20CHOCl:!2-), 2.19·1.22 (16H, m, -CI:!2-); 13C NMR (6 ppm): 199.94,
139.68, 136.83, 132.68, 128.75 (2), 128.53 (2), 128.39 (2), 128.09 (2), 126.83,
98.72, 67.45, 62.25, 53.54, 33.91, 30.68, 29.56, 29.36, 27.55, 25.99, 25.40,
19.62; MS (mle): 380 (W), 296 (M+ - DHP), 105 (C6H5-C=O).
1,2 Bisphenyl-10-tetrahydropyranyloxy-decanone (5Jb)
lA, "max (thin film): 3092-3025 (Ar-H), 2933~2858 (C-H), 1683 (C=O), 1585
(C=C) em- l ; 'H NMR (6 ppm): 8.01-7.15 (10H, m, Ar-Il), 4.56 (lH, I, J=3.53 Hz,
-OCliO-), 4.54 (lH, I, J=7.29 Hz, -CIi-), 3.84, 3.71, 3.47 ,3.35 (4H, 4xm,
-CI:!20CHOCl:!2-), 2.16-1.26 (20H, m, -CI:!2-); 13C NMR (6 ppm): 199.93,
139.70, 136.84, 132.65, 128.71 (2), 128.50 (2), 128.35 (2), 128.07 (2), 126.79,
98.67,67.51,62.18,53.53,33.96,30.68,29.61,29.45, 29.26 (2), 27.60, 26.09,
25.40, 19.60; MS (mle): 408 {WI, 324 (M+ - DHP), 105 (C6HS-C=O).
1,2-Sisphenyi-12-tetrahydropyranyloxy-dodecanone (S3c)
mp: 59-59.5 0C. lA, "max (KBr): 3092-3025 (Ar-H), 2933-2858 (C-H), 1683
(C=O), 1585 (C=O) em-1; 'H NMR (6 ppm): 8.01-7.15 (10H, m, Ar-lf), 4.57 (lH,
I, J=3.50 Hz, -OCIiO-), 4.53 (lH, I, J=7.22 Hz, -CIl-), 3.85, 3.72, 3.49, 3.37 (4H,
4xm, -C!:I20CHOCIl2-), 2.15-1.23 (24H, m, -CIl2-); 13C NMA (6 ppm): 200.12,
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139,82, 137,00, 132,74, 128,81(2), 128,61(2), 128.46(2), 126,20(2), 126,88,
96,84, 67,69, 62,34, 53.67, 34.06, 30.60, 29.76, 29.59, 29.51(2), 29.45(2),
27.72,26.23,25.51, 19.71: MS (m/e): 436 (M+), 352 (M+ - DHPj, 105 (CSHS"
C=O),
B. Synthesis of 1,1 ,2-trlsphenyl·alkan-l ,n·diol (55).
A Grignard reagent was prepared from magnesium (432mg, 18.0 mmol)
and bromobenzene (2.36 g, 15.0 mmol) in the presence 01 a crystal of iodine in
100 mL of dry ether. The preparation of Grignard reagent required 4 hrs at room
temperature (23 DC). A solution of ketone 53 (3.0 mmol) in dry ether was treated
with the excess of the Grignard reagent for S hrs under nilrogen at room
temperature (23 DC) and was then hydrolysed with 50 mL. of 10% aqueous
ammonium chloride. The ether phase was washed with water (5 x 50 ml), dried
and evaporated to give the crude tertiary alcohol intermediate 54. The oily
residue refluxed with 95% ethanol in the presence of PPTS (100 mg, 0.40
mmol) for 3 hrs. After evaporation of the solvent, the residue was taken with
ether. The ethereal phase was washed with water (5 x 50 ml), dried and
evaporated to an oil. The crude 55 was used as such for next dehydration step.
Flash column chromatography (hexane:acetone, 7:1) could produce a pure 55
(85% yield from 53).
1,1 ,2~Trlsphenyt-octan-l,8-diol (55a)
IA. \lmax (thin film); 3600-3300 (OH),.3090-3015 (Ar-H), 2950·2850 (C-H),
1600 (C=C) cm-l ; lH NMA (S ppm); 7,59-6,96 (15H, m, Ar-ll), 3,69 (1H, dd,
J=11.42 Hz, J':2.B6 Hz, 'CJ::i-), 3.50 (2H, t, J=6.S2 Hz, ·Ctl20H), 2.57 (lH, br 5,
COl!), 1,90-1,06 (11H, m, -(C!i2)5 and -CH20!:l); 13C NMA (S ppm); 146,27,
59
145.98, 139.97, 129.96(2), 128.10(2) 127.60(2), .127.49(2), 126.60, 126.26,
126.20(2),126,00, 125.61(2), 80.B6, 62.76, 54.13, 32.52, 30.00, 29.22, 27.80,
25.41; MS (m/e): no M+, 357 (M+ • OH). 356 (M+ • H20). 183
(C6H5C(OH:C6H5)·
1.1.2-Trisphenyr-decan-1,1 a-diol (55b)
The crude inlermediale 5Sb was used lor next dehydration step without
purification.
1.1.2-Trispheny]-dodecan-','2·diol (SSe)
IR. umax (thin film): 3600·3300 (OH), 3090·3015 (Ar-H), 2950·2850 (e-H),
, 600 (C:::C) em"; 1H NMR (8 ppm): 7.59-6.96 {15H. m, AT-til, .3.69 (1 H, dd,
J=11.42 Hz, J'=2.86 Hz, ·CH-), 3.60 (2H, I, J=6.62 Hz, -CH20H). 2.50 (1H, br 6,
COli), 1.90-1.06 (19H, m, -(Cl:!219- and -CH20l:!); 13C NMA (& ppm): 146.31,
145.97,140.00,129.99(2),128.14(2),127.62(2), 127.48(2), 128.80, 128.24(3),
128.02,125.80(2),80.90,62.98,54.13,32.72,30,02, 29.47(2), 29.41, 29.34(2),
27.86, 25.63; MS (m/e): no M+, 413 (M+ • OH), 412 (M+· H20), 183
(C8 H5C(OH)C6HS)'
C. Synthesis of x,y,y4risphenyl-x-olken-'-o! (56).
The oily 55 (2.5 mmol) was dehydrated in 100 mL toluene in the presence
of pTSA (100 mg, 0.56 mmol) at reflux for 2 hrs. After evaporation of the solvent,
the residue was extracted wifh ether and waler (5 x 50 mL), dried and
evaporated to an colorless product 56. Flash column chromatograph
(hexane:acetone, 9:1) yield a viscous oil (99% yield from 55).
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7,8,S-Trisphenyl-7w octen·1·ol (56a)
mp: 90.Sw 91.5 oC; lA, umax (KBr): 3330 (br, OH), 3100-3000 (Ar-H), 2925-2825
(C-H), 1600 (C=C) cm-1; lH NMA (0 ppm): 7.34-6.86 (15H, m, Ar-.!:!), 3.55 (2H, t,
J=:6.60 Hz, -Cti20H), 2.43 (2H, m, -C=C-C.t:I2-), 1.50-1.19 (9H. m, -(C.t:I2l4- and
-CH20.!:i); 13C NMR (0 ppm): 143.43, 142.92, 142.40, 140.89, 138.92,
130.65(2), 129.52(2), 129.43(2), 128.08(2), 127.76(2), 127.30(2), 126.53,
126.10,125.67,62.91,35.72,32.58,29.33,28.72,25.30; MS (mle): 356(M+),
269(M+ - CSH100H).
9,10,10-Trisphenyw 9-decen·1-ol (5Gb)
IR, umax(lhin film): 3330 (br, OH), 3100-3000 (Ar-H), 2925-2825 (C-H), 1600
(C==C) cmwl ; 1H NMA (o ppm): 7.34-6.86 (15H, m, Ar-ti), 3.51 (2H, I, J=6.73 Hz,
-CJi20H), 2.43 (2H, m, -C=C-C!i2-), 1,45-1.14 (13H, m, -(C!i2)6- and
-CH20Ji); 13C NMR (6 ppm): 143.22, 142.74, 142.19, 140.77, 138.84,
130.52(2),129.26(4),127.89(2),127.60(2), 127.14(2), 126.36, 125.91, 125.49,
62.41,35.62,32.23,29.35(2),28.99,28.58,25.43; MS (m/e): 384 (W), 269 (W
- C7HI40H).
11,12,12-Trlsphenyl-11-dodecen-1-ol (S6c)
lA, umax(lhin film): 3330 (br, OHI, 3100-3000 (Ar-H), 2925-2825 (C-H), 1600
(C==C) cm-1; lH NMA (0 ppm): 7.34-6.S6 (15H, m, Ar-ti), 3.59 (2H, t, J=6.86 Hz,
-CJi20H), 2,43 (2H, m, -C=C-CJi2-), 1.52-1.15 (17H, m, -(CJi2)8- and
-CH20.!:i); 13C NMR (a ppm): 143.43, 142.93, 142.40, 141.00, 138.92,
130.65(2), 129.47(2), 129.41(2), 128.01(2), 127.72(2), 127.26(2), 126.48,
126.01, 125.61,62.91, 3S.76, 32.60, 29.58,29.45,29.36(2),29.17,28.75.
25.63, MS (m/e): 412 (W), 269 (M+ - C9HI80H).
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O. Synthesis of 1-bromo-x,y,y·trisphenyl-x-alkene (57)_
A solulion of the alcohol 56 (2.25 mmoO, carbon tetrabromide (2.98 g, 9.00
mmol) and triphenylphosphi'le (2.36 g. 9.00 mmol) in dry ether (100 mL) was
stirred at room temperature (23 0C) for 24 hrs under a nitrogen atmosphere. The
triphenylphosphine oxide precipitate was filtrated and the resulting solution was
washed thoroughly with waler (5x25 mL), dried and evaporated to an oil. The
crude malerial was purified by flash column chromalography (hexane:acetone.
99:1) to give the bromine 57 in 86% yield.
1·Bromo-7,8,8-trisphenyl-7-octene (57a)
IR. "max (thin film); 3090-3015 (Ar-H), 2930-2850 (C-H), 1600 (C=C) cm-1; 1H
NMA (0 ppm): 7.37'6.86 (15H, m, Ar'Il), 3.31 (2H, I, J=8.84 Hz, ,Cl:!28r), 2.43
(2H, m, ·C=C·Cll2·), 1.74 (2H, p, J=7.20 Hz, ,Cll2CH2B,), 1.34-1.21 (8H, m,
-(C.ti2l3-); 13C t-JMR (8 ppm): 143.42, 142.88. 142.32,140.76, 139.23,
130.84(2),129.53(2), 129.41(2),128.14(2), 127.79(2), 127.33(2), 126.59,
126.13, 125.71, 35.84, 33.90, 32.60, 28.70, 28.54, 27.79; MS (m1e): 418 (M+),
420 (M++ 2), 289 (M+ ·C5H,oBr).
1-Bromo-9,la, lD-trisphenyl-g-decene (57b)
lA, umax (Ihin film): 3090-3015 (Ar-H), 2930-2850 (C-H), 1600 (C=C) cm-1; 1H
NMA (0 ppm): 7.37-8.86 (ISH, m, Ar-Il), 3.38 (2H, I, J=6.86 Hz, ·Cll28r), 2.42
(2H, m, -C=C-CI:!2'), 1.79 (2H, p, J=7.38 Hz, ·Cll2CH2Br), 1.34·1.17 (10H, m,
-(CI::!.2)S-); 13C NMR (8 ppm): 143.43,142.93, 142.40, 140.94, 138.91,
130.67(20, 129.52(2). 129.45(2), 128.07(2), 127.75(2), '27.30(2), 128.53,
126.08, 125.68, 35.76, 34.05, 32.71, 29.45, 28.98,28.69,28.52, 28.02. MS
(rnle): 446 (M+), 448 (M+ + 2), 269 (M+ - C7H14Br).
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1-Bromo-11 ,12,12-trisphenyl-11-dodeeene (57e)
IR, umax (thin IiIm): 3090-3015 {Ar-H), 2930·2850 (C-H), 1600 (C=O) em_1; 1H
NMR (o ppm): 7.37-6.86 (15H, m, Ar-ti), 3.38 (2H, I, J::6.86 Hz, -Cl:!.2Br), 2.42
(2H, m, -C=C-Cl:!..2-), 1.82 (2H, p, J=7.20, -Cl:!.2CH2Br), 1.34-1.16 (14H, m,
-(C!:!2)7-); l3C NMA (S ppm): 143.48, 142,98, 142.48, 141.05, 139.01,
130.69(2), 129.53(2), 129.46(2). 128.07(2). 127.73(2), 127.30(2), 126.53,
126.07.125.66,35.82,34.04,32.80,29.59,29.33(2), 29.18, 28.77, 28.68.
28.14; MS (m1e): 474 (M+), 476 (M+ + 2), 269 (M+ - C9H18Br).
E. Synthesis of 1-[(2'-aminoethyl)amino]-x,y,y-trisphenyl-x-alkene (58).
Under a nitrogen atmosphere, ethylenediamine (900 mg, 15.00 mmol) was
added to a solution of the bromide 57 (1.50 mmol) in 80 mL of dry methanol.
After boiling for two days under reflux (sometimes longer reaction period was
required), the solvent was evaporated. The resulting residue was dissolved in
ether (150 mL) and washed with a solution of NaHC03 (30 mL, 5% aqueous)
and with water (5x30 ml). The ethereal phase was dried and evaporated to a
viscous oil 58. The yield was 90%.
1-I(2'-Aminoethy1)aminoj-7,8,8-trlsphenyl·7-octene (SSa)
lA, "max (thin film): 3290 (br, N-H), 3090-3015 (Ar-H), 2930-2850 (C-H), 1850
(N-H, bending), 1600 (C=C) cm~1; 1H NMR (5 ppm): 7.35-6.86 (15H, m, Ar-H),
2.76, 2.61 (4H, 2xt, J=6.06 Hz, -NHC.!::i2Cl:I.2NH2), 2.51 (2H, I, J::7.25 Hz,
-Cti2NH-), 2.43 (2H, m, -C=C-C!:!2-), 1,80 (3H, s, br, -Nl::::!.- and -Nti2), 1.38-1.18
(8H, m, -(C!i2)4-); 13C NMA (6 ppm): 143,30,142.80, 142.25, 140.80, 138.91,
130.54(2), 129.38(2), 129.32(2), 127.98(2), 127.64(2), 127.18(2), 128.41,
125.96, 125.54, 52.32, 49.65, 41.54, 35.65, 29.B4, .29.41, 28.65, 26.B6; MS
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(mle): 398 (M+). 368 (M+ -CH2NH2), 355 (M+ - CH2CH2NH), 269 (M+ -
CSH, ONHCH2CH2NH2).
"[(2'-Aminoethyl)amino]-g,l 0,1 O·trisphenyr·g·decene (58b)
lA, \lmax (lhin film): 3290 (br, N·H), 3090·3015 (Ar-H), 2930·2850 (C·H), 1650
(N-H, bending), 1600 (C=C) cm-1; lH NMR (15 ppm): 7.34-6.86 (15H, m, Ar-.l:i) ,
2.78, 2.65 (4H, 2xt, J=S.03 Hz, ·NHCH2C.t!2NH2), 2.56 (2H, I, J=7.23 Hz,
-C.!:i2NH·), 2.42 (2H, m, -C."C·C.!::l2-), 1.58 (3H, S, br, -Nti- and -N!i2), 1.43-1.17
(12H, m, ·(CJ:j2)6·)' 13C NMfl (0 ppm): 143.38. 142.91. 142.36. 140.98. 138.90.
130.62(2), 129.46(2), 129.40(2), 126.00(2). 127.67(2). 127.23(2), 126.44,
126.00,125.58,52.49,49.85,41.70,35.74,30.06, 29.52, 29.34, 29,12, 28.72,
27.22; MS (m/e): 426 (M+), 396 (M+ - CH2NH2), 383 (M+ - CH2CH2NH). 269
(M+ - C7H,4NHCH2CH2NH2).
'-((2'-Amfnoethyl)amlno]-11,12.12-trisphenyl-l1-dodecene (Sac)
lA, umax (thin film): 3290 (br, N-H), 3090·3015 (Ar-H), 2930·2850 (C·H), 1650
(N·H, bending), 1600 (C.C) em-I; 'H NMR (0 ppm): 7.34-6.86 (15H, m, Ar·Jj),
2.80, 2.66 (4H, 2xl, J=6.03 Hz, ·NHCtl2C.I:!2NH2), 2.Eg (2H, t, J=7.23 Hz,
-Ctl2NH-), 2.42 (2H, m, -C=C-CJ:j2-), 1.64 (3H, S, br, -NH- and -Ntl2), 1.48-1.15
(16H, m, -(C<l2)8-): 13C NMR (8 ppm): 143.43, 142.97, 142.41, 141.05, 138.91,
130.66(2), 129.49(2), 129.43(2), 128.03(2), 127.70(2), 127.26(2), 126.46,
126.02, 125.61.52.49, 49.90, 41,66, 35.79, 30.09, 29.61, 29,49(2), 29.43,
29.21, 28.76, 27.33; M5 (m/e): 454 (M+), 424 (M+ - CH2NH2), 411 (M+-
CH2CH2NH), 269 IM+ - C9H, BNHCH2CH2NH2).
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F_ Synthesis of 1-{cis-[(2'-aminoethyl)aminojdichloroplatinum(II)}_x,y,y_
trisphenyl-x-alkene (40).
A solution of potassium telrachloroplatinate (II) (219 mg, 0.528 mmol) in
7.5 mL of a mixture of DMF and water (2:1) was added to a warm (35 0C)
solution of diamine 58 (0.528 mmol) in 5 ml of DMF. The resulting mixture
(pH=9-10) was stirred in the dark for 2-3 days until the pH value reached 4·5.
Then, one drop of N,N-dimethylsulfoxide was added and the stirring was
continued for 2 hrs. The solvent was evaporated and the residue was
suspended tn saturated potassium chloride solution (30 mL). A vigourou.~
stirring was essential in order to pulverized the lumps of platinum (II) complex
40 The resulting suspension was fillered, washed with water (100-250 mL), and
dried in a desiccator. The product can be further purified either by flash column
chromatography or by preparative TLC (CH2CI2:CH30H, 98;2). The crude yield
was aroLmd 80%.
-'·{Cis-f(2'-aminoethyl)amlno]dlchloroplatinum (1I)}-7,a,a-trisphenyl-7-octene
(400)
mp > 210°C (dec,): JR, "max (KBr): 3250-3150 (N-H), 3090-3015 (Ar-H), 2930-
2850 (C-H), 1600 (C=C) em· l ; 'H NMR (5 ppm): 7.33·6.86 (15H, m. Ar·lJ), 5.51,
4.89, 4.72 (3H, 3xbr 5, -Nli- and -Nli2), 3.35, 3,09, 2.72 (6H, 3xbr 5,
-Cl:l2NHCti2Ctl2NH2), 2.39 (2H, m, -C=C-Ctl2-), 1.70,1.54 (2H, 2xbr s,
-Ctl2CH2NH·), 1.40·1.10 (6H, m, -(Cti2)3-); 13C NMR (5 ppm): 140.35, 142.86,
142.23,140.60,139.21,130.66(2),129.52(2), 129,41(2), 128.17(2), 127.82(2),
127.33(2), 126.60, 126.14, 125.71, 55.17, 53.23, 47.03, 35.61, 29.11, 28,44,
27.20,26.02. Anal. cared. for C2sH34C12N2PI: C 50.60, H 5.17, N 4.22; found:
C 50.63, H 5.20, N 4.19.
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1~{Cjs-[(2'·amjnoethyl)aminoldjchJoroplatjnum (1I)}~9,10,10-trisphenyl-9­
decene (40b)
mp> 2100C (dec.); lA, umax (KBr): 3250·3150 (N-H), 3090-3015 (Ar-H), 2930-
2850 (C-H), 1600 (C=C) em-'; 1H NMA (5 ppm): 7.33-6.86 (ISH, m, Ar-!:i), 5.56,
5.30,5.04 (3H, 3xbr S, -N.!i- and -N!i.2), 3.38,3.19,3.05,2.72 (6H, 4xbr S,
-Cli,NHCl:l2C!:i,NH,), '.40 ('H, m, -C=C-C!:i,-), 1.67, '.48 ('H, 'xbr s,
-Cli,Cl:l2NH-), 1.40-1.10 (10H, m, -(Cli')5-); 13C NMA (5 ppm): 143.43,
14'.95, 14'.40,140.9',139.05, 130.69('),1'9.53('),1'9.46(2), "8.10('),
127.77(2),127.31(2),126.56,126.09,125.68,55.20, 53.43, 47.20, 35.79, 29.71,
29.52,29.02,28.76,27.39,26.37. Anal. calcd. for C30H3SC12N2Pt: C 52.01, H
5.54, N 4.05; found: C 52.05, H 5.51, N 4.02.
1~{C[s·[(2'-amlnoethyl)amlno]dichJoroplatinum (11)}-11,12,12-trlsphenyJ-11-
dodecene (40c)
mp > 210 'C (dec.); lA, umax (KBr): 3250-3150 (N-H), 3090-3015 (Ar-H), 2930-
2850 (C-H), 1600 (C=C) em-I; 1H NMA (5 ppm): 7.33-6.86 (15H, m, Ar-!:i) , 5.6',
5.01,4.84 (3H. 3xbr s, -N.l:i- and -N.!::f.2). 3.50,3.15,2.88,2.76 (6H, 4xbr s,
-Cl:l2NHCl:l2Cl:l2NH,), '.40 (2H, m, -C=C-Cl:l2-), 1.68,1.50 ('H, 2xbr s,
-Cl:l2CH,NH-), 1.40-1.10 (14H, m, -(Cli')7-). 13C NMA (5 ppm): 143.44,
142.97, 142.42,141.00,138.91, 130.69('), 129.51(2), 129.45(2), 128.07(2),
127.75(2), "7.28(2), 126.53, 126.05, 125.65,55.40,53.39,45.86,35.83,29.67,
29.43(2), 29.23(2), 28.79, 27.40, 26.54. Anal. calcd. for C32H42C12N2Pt: C
53.32, H 5.89, N 3.89; found: C 53.28, H 5.90, N 3.92.
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3.2 !.!:l..Y.i1r2 Antitumor Activity
3.2.1 Materials of Mlcrocytostasis Assay
A. Drugs:
39a-d. 40a-c and 41 synthesized as described previously;
Cisplalin obtained from Sigma Chemical Company, USA;
Tamoxifen obtained from Aidrich Chemical Company, Inc., USA.
B. CeJllines and culture:
Human breast cancer cell lines: MCF-7 and MDA-MB-231 were obtained from
the American Type Culture Colleclion, Maryland, USA. Both MCF-7 and MDA-
MB-231 cells were cultured in RPMI-1640 supplemented wilh 2mM glutamine,
101;>/0 fetal bovine serum (Gibeol, Burlington, Ontario, Canada) and 100 U
gentamycin/mJ (Sigma Chemical Company, USA).
C. Phosphate Buffered Saline (PBS, pH=7.4) prepared from PBS tablets
(Oxoid, Unipath Ltd., England), dissolved in water as per manufacturer's
instructioos.
D. Microtitre Plates, 96 wells obtained from Flow Lab. Inc.• McLean, Virginia,
USA.
E. MTr and DMSQ obtained from Sigma Chemical Company, USA.
F, Plate Reader: Behring Elisa Processor II (Behring, Malburg, Germany).
3.2.2 Method of Mlcrocytostasls Assay
The MTT assay was carried out essentially as described by J.
Carmichael and eo-work6rs.72 Under sterile conditions. the 40 mM solution of
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drugs in DMSO was diluted with fresh medium (APMI- 1640) to a concentration
of 400 11M, then different drug dilutions were prepared in the culture medium
(range 0.1· 400 fl.M). A total of 100 III cell culture medium APMI·164Q
containing 2000 viable cells was plated per WGJI into 96·weU microtitre plate,
and preincubated for 24 hours at 37 "C in a 5% C02 atmosphere. Then, the
medium was removed from the cells, and 100 III uf fresh medium containing
various concentrations of a drug was added to the cultures. Tests were
performed in B wells for each tesl dilution, with appropriate control wells which
received 100 III of medium only. The cells were incubated with the drug for 72
hours. Next, the medium was removed and the cells were washed with the
slerile phosphate·buffered saline (PBS, pH=7.4). Cell survival was evaluated
with MlT by the addition of a 50 III solution containing 2.5 mglmL In PBS:RPMI·
1640 (1:4, v/v). After 4 hours incubation at 37 ce, the solution was aspirated
from each well, and 100 ilL DMSO was added to dissolve the precipitate of
reduced MTT. The plates were shaken on a plate shaker for 15 minutes, then
the absorbance was speclrophotometrically determined al 570 and 630 nm with
a Behring Elisa Processor II (Behring, Marburg, Germany). Results from the
plate reader were expressed as follows:
Percentage Cell SUlvival at Each Dilution
Mean Absorbance at Each Dilution
X 100.
Mean Control Absorbance
A dose response curve of percentage ceU survival (ordinate) against drug
concentration (abscissa) was constructed.
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APPENDIX
The selected IA. lH NMR, 13C NMR of the synthetic samples were
arranged according to the order in which they appear in the text. For the
instruments employed, see General Procedures in Charpter 3.
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